Public tenders for business in Bethesda United States

Find all Business tenders in the world.
Finding business opportunities has never been easier.

Results for business. Make a new search!

HLA Reagents for Transfusion Medicine

Department of Health and Human Services, National Institutes of Health | Published April 10, 2017  -  Deadline April 25, 2017
cpvs

The National Institutes of Health (NIH) intends to award a fixed priced purchase order on a sole source basis to Omixon Inc. Salem, MA, 01970 to procure ten (10) New Generation Sequencing (NGS)-based HLA Genotyping Assay, Holotype HLA 24/7 - Configuration A1 for the existing government owned Illumina® MiSeq instrument. This instrumentation is used by Department of Transfusion Medicine, Human Leukocyte Antigen (HLA) Lab to determine the HLA type of a patient or donor. The specified reagents are necessary to perform the highest resolution typing possible for HLA testing which is necessary for the workup of mismatched transplants performed at NIH via the unrelated and haploidentical transplant protocols. The Holotype HLA 24/7provides targeted amplification and library preparation reagents for comprehensive gene coverage of multiple HLA loci and the most accurate, high resolution genotying available, with no reflexive testing required. These reagents are the only kits known which are currently available in the United States utilizing the technology that the NIH HLA laboratory deems essential to employ, including preparatory steps to achieve the final product. Omixon is the sole licensor of the product. Training in the use of Omixon's products is exclusively provided by Omixon, a designated reference lab, Agent or Distributor. Omixon's products are all protected trade secrets. There are no potential substitutes. This acquisition is being conducted under the authority of the FAR Subpart 13.106-1(b)(i), Contracting officers may solicit from one source if the contracting officer determines that the circumstances of the contract action deem only one source reasonably available. Interested concerns capable of providing the same or similar products or services as described in this notice may submit a capability statement outlining their capabilities. Capability Statements must be received within the time set forth in this synopsis to be considered by the Government. A determination to compete this proposed contract based on responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Each response should include the following Business Information:a. DUNS.b. Company Name, address, POC, Phone and Email addressc. Current GSA Schedules or NAICS codes appropriate to this Award.d. Type of Company (i.e., small business, 8(a), woman owned, hubZone, veteran owned, etc.) as validated in System For Award Management (SAM). All offerors must register on the SAM located at http://www.sam.gov/portal/SAM/#1 e. Capability Statement Comments to this announcement may be submitted to the Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, electronically to the attention of Malinda Dehner, Contract Specialist, dehnerm@cc.nih.gov by the due date and time marked in this notice.

HIGH RESOLUTION AND SEQUENCE BASED REAGENTS FOR TRANSFUSION MEDICINE

Department of Health and Human Services, National Institutes of Health | Published April 10, 2017  -  Deadline April 25, 2017
cpvs

This is a notice of intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested. The National Institutes of Health, Clinical Center (CC) intends to award a fixed price purchase order to Qiagen, Valencia CA 91355-1005 on a sole source basis to procure specialized reagents and testing kits for use on the existing government-owned Qiagen GenoM-6 BioRobot EZ1® and the EZ1® Advanced XL isolation instruments used for automated nucleic acid extraction. This requirement is to provide reagents and testing kits to the Human Leukocyte Antigen, HLA lab, Services Section, that has been quality controlled for use on this specific instrumentation. The quality control process is an American Society for Histocompatibility and Immunogenetics (ASHI) and Clinical Lab for Improvements Amendment (CLIA) regulation as the consumables for patient care must be found suitable and in accordance with the manufacturer's instructions. The Qiagen EZ1 reagents and kits are necessary to perform high resolution and sequence based testing for transplant patients and donors who must both be matched for peripheral blood stem cell and cord blood transplants. No transplants can occur unless these high resolution results are received and approved by a CC physician. Qiagen is the sole manufacturer and distributor of the EZ1 Kit chemistry. The comprehensive system of instruments and consumables is necessary to produce a complete testing result. The below supply and quantity is required for a twelve (12) month time period from award:Item#                                     Description                                    Quantity951054                 EZ1 DNA Blood 350 ul kit (48)                               84 This acquisition is being conducted under the authority of the FAR Subpart 13.106-1(b)(i), Contracting officers may solicit from one source if the contracting officer determines that the circumstances of the contract action deem only one source reasonably available. Interested concerns capable of providing the same or similar products or services as described in this notice may submit a capability statement outlining their capabilities. Capability Statements must be received within the time set forth in this synopsis to be considered by the Government. A determination to compete this proposed contract based on responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement.Each response should include the following Business Information:a. DUNS.b. Company Name, address, POC, Phone and Email addressc. Current GSA Schedules or NAICS codes appropriate to this Award.d. Type of Company (i.e., small business, 8(a), woman owned, hubZone, veteran owned, etc.) as validated in System For Award Management (SAM). All offerors must register on the SAM located at http://www.sam.gov/portal/SAM/#1 e. Capability StatementComments to this announcement may be submitted to the Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, electronically to the attention of Malinda Dehner, Contract Specialist, dehnerm@cc.nih.gov by the due date and time marked in this notice.

RDM software support

Department of Health and Human Services, National Institutes of Health | Published April 10, 2017  -  Deadline April 20, 2017
cpvs

This is a notice of intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested. The National Institute of Health (NIH), Clinical Center (CC) intends to award a fixed price purchase order to Bayer Healthcare, LLC. on a sole source basis to procure maintenance coverage for software support of all software products associated with the full operation of the  Bayer Radimetrics Enterprise Platform. the radimetrics software copyright  is owned by Bayer Healthcare abnd is licensed to Radiology & imaging Sciences for its own use.The North American Industry Classification System (NAICS) code for this acquisition is 541519 , and the size standard is $27.5M This acquisition is being conducted under the authority of the FAR Subpart 13.106-1(b). Interested concerns capable of providing the same or similar products or services as described in this notice may submit a capability statement outlining their capabilities. Capability Statements must be received within the time set forth in this synopsis to be considered by the Government. A determination to compete this proposed contract based on responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement.Each response should include the following Business Information:a. DUNS.b. Company Name, address, POC, Phone and Email addressc. Current GSA Schedules or NAICS codes appropriate to this Award.d. Type of Company (i.e., small business, 8(a), woman owned, hubZone, veteran owned, etc.) as validated in System For Award Management (SAM). All offerors must register on the SAM located at http://www.sam.gov/portal/SAM/#1 e. Capability Statement Comments to this announcement may be submitted to the Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, electronically to the attention Gail Akinbinu,Contract Specialist,gakinbinu@cc.nih.gov by the due date and time marked in this notice.

Production of blocking Rabbit Monoclonal Antibody against human CD97

Department of Health and Human Services, National Institutes of Health | Published August 31, 2016  -  Deadline September 6, 2016
cpvs

Contracting Office AddressDepartment of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E1644, Bethesda, MD 20852, UNITED STATES.DescriptionThe National Cancer Institute (NCI), Cancer Center Research (CCR), The Laboratory of Genitourinary Cancer Pathogenesis (LGCP) plans to procure on a sole source basis for 0a custom rabbit monoclonal blocking antibody directed against human CD97 manufactured by Abcam Burlingame, 863 Mitten Road, Suite 103-104, Burlingame, CA 94010-1303. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The North American Industry Classification System code is 325414 and the business size standard is 1250. Period of performance shall be for twelve (12) months from date of award. It has been determined that there is no opportunity to acquire green products or services under this contract. The Purpose of this acquisition is to procure Production of blocking Rabbit Monoclonal Antibody against human CD97. The human CD97, a G protein-coupled receptor, is absent in normal epithelial cells but increases in expression in parallel with malignant grade in several carcinomas. Current investigative efforts toward understanding the role of CD97 in cancer biology has been hindered by the lack of a reliable CD97 blocking antibody. A blocking antibody does not have a reaction when combined with an antigen, but prevents other antibodies from combining with that antigen. Screening of current commercially available CD97 antibody sources has unfortunately failed to uncover any polyclonal or monoclonal antibodies able to block CD97 binding. Therefore, the LGCP has a need to produce a rabbit monoclonal CD97 blocking antibody to further our investigative efforts, and provide a useful tool for the CD97 research field. Antibodies from rabbits are generally of higher affinity than those from mice. Results obtained from the contractor and other researchers indicate that the binding affinity of rabbit monoclonal antibodies is on average 100 times higher, offering better sensitivity and specificity in biological assays. Rabbit monoclonal antibodies recognize many antigens that are not immunogenic in mice, including small molecule haptens, some cell surface epitopes, modified sites (e.g., phosphorylation, acetylation, methylation, glycosylation, etc.) and most rodent proteins. The rabbit system offers 40 times as many lymphocytes compared to mouse and the 240E cell line used for fusion is much more robust than any of the mouse cell lines used for fusion. Because of the large size of the rabbit spleen, more fusion experiments can be performed, making hybridoma generation at industrial scale a feasible task. The contractor shall generate up to 9 hybridoma subclones from as many as 3 parent hybridoma cell lines chosen by NCI/LGCP as a result of screening. The production required to blocking Rabbit Monoclonal Antibody possesses the following salient characteristics: Phase I: Rabbit Polyclonal Antibody Service - Immunization of two (2) rabbits using standard immunization of five (5) injections and collection of one (1) pre-bleed and two (2) test bleeds per rabbit.- Monitor antiserum titer using standard ELISA.- Counter-screen with Fc fusion protein.- Discuss titer results with NCI to select rabbit for splenectomy.- Final IV and splenectomy (Final IV must be scheduled within 4-8 weeks of last regular injection boost). Phase IIa: Rabbit Monoclonal Antibody Service - Isolate all the lymphocytes from one rabbit spleen.- Store all remaining lymphocytes in liquid nitrogen for up to three (3) months after the termination of the project. Phase IIb: Rabbit Monoclonal Antibody Service - Perform hybridoma fusion of 80 x 96-well plates.- Perform standard ELISA screening of 80 x 96-well plates.- Expand all positive hybridomas to 24-well plates and perform confirming standard ELISA.- Counter-screen with Fc Fusion Protein.- Transfer and deliver all standard ELISA positive multi-clone supernatants (1 ml each) for a two week screening by NCI. Phase IIIa: Rabbit Monoclonal Antibody Service - Subclone up to 3 multclone hybridomas chosen by NCI.- Perform standard ELISA screening of supernatants.- For each hybridoma chosen, deliver supernatants (1 ml each) from subclones for a two week screening by NCI.- Freezing and storage of backup (3) multiclone hybridomas. Phase IIIb: Rabbit Monoclonal Antibody Service - Expand up to nine (9) final hybridoma subclones from each parental clone as frozen cells.- Store subclones for three (3) months following project completion. Phase IIIc: Rabbit Monoclonal Antibody Service- Culture one (1) hybridoma subclone (1L).- Perform two (2) hybridoma supernatant harvest collections.- Perform standard ELISA screening and spectroscopic concentration determination of supernatant.- Purify the hybridoma supernatant using a Protein A column.- Analyze the purify sample via gel electrophoresis, spectroscopic concentration determination, and ELISA. QUESTIONS ARE DUE: September 2, 2016 This is not a solicitation for competitive quotations. However, if any interested parties, especially small businesses, believe they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. A copy of the capability statement must be received in the NCI Office of Acquisition on or before 11:00 AM EST on September 6, 2016. All questions must be in writing and can be faxed (240) 276-5401 or emailed to Kathy Elliott, Contract Specialist at Elliottk@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification on Sam.gov, www.sam.gov. No collect calls will be accepted. Please reference solicitation number N02RC62562-61 all correspondence.

Theta-Burst Stimulation as a Treatment for Reducing Cocaine Use

Department of Health and Human Services, National Institutes of Health | Published August 31, 2016  -  Deadline September 6, 2016
cpvs

INTRODUCTION This is a pre-solicitation non-competitive (notice of intent) synopsis to award a contract without providing for full or open competition (including brand-name). THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR PROPOSAL. A SOLICITATION WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The National Institute on Drug Abuse (NIDA), Consolidated Station Support and Simplified Acquisitions (CSS/SA) Branch intends to negotiate and award a purchase order to Magventure, Inc  for a Human TMS system without providing for full and open competition (including brand-name). NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE The intended procurement is classified under NAICS code 423490 with a Size Standard of 150 Employees. REGULATORY AUTHORITY The resultant contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular  (FAC) 2005-89 dated July 15, 2016. This acquisition is for a commercial item or service and is conducted under the procedures as prescribed in FAR subpart 13-Simplified Acquisition Procedures. This acquisition is NOT expected to exceed the simplified acquisition threshold STATUTORY AUTHORITY This acquisition is conducted under the authority of the authority of FAR Subpart 13.106.1.b-1 DESCRIPTION OF REQUIREMENT The NIDA-IRP requires (1) a transcranial magnetic stimulation (TMS) device for the experimental application to treat substance abuse (e.g., cocaine dependence). A recent study from Dr. Antonello Bonci’s lab (NIDA/IRP Scientific Director) showed that optogenetic stimulation of the prelimbic cortex can remove compulsive cocaine seeking behavior in rats trained to self-administer cocaine in the face of a punishment. To translate the findings from the animal model to human clinical studies and to better understand the underlying neurobiological mechanisms, development of non-invasive brain stimulation coupled with fMRI measurements is necessary. We plan to use the TMS device to a) understand acute brain circuit alterations in the presence of TMS using neuroimaging in both control and cocaine using participants, b) understand long-term brain circuit alterations related to chronic application of TMS using neuroimaging in cocaine using participants, and 3) investigate the efficacy of the TMS intervention in reducing cocaine use in cocaine using participants.   Specifically, the NIDA-IRP, Office of the Scientific Director requires a MagVenture X100 with MagOption Magnetic Stimulator, 230V or its equal. For reference, the MagVenture X100 with MagOption Magnetic Stimulator, 230V, supporting equipment, and TMS coils meet the needs of this requirement includes the following Part Numbers (1each):  9016E0731, 9016D0031, 9016E0482, 9016E0501, and 9016B0151.   The brand name human TMS stimulation system and coil must meet the following requirements:   1.    It must be equipped with a strong power supply and a transcranial magnetic stimulation (TMS) coil that is cooled and specific for stimulating the human brain. 2.    The TMS system and coil should be able to continuously administer theta-burst stimulation (TBS) at 100% duty cycle without overheating and with clinical accuracy. 3.    The power supply and related hardware and software must be able to provide repetitive TBS stimuli that, at a minimum, meets the following requirements: a stimulation intensity that represents 110% of the average resting motor threshold of clinical participants, must be able to administer at least 4 minutes of intermittent TBS delivered once per hour for up to 8 hours a day, and the coil must be actively cooled. 4.    The equipment must have capabilities to elicit motor evoked potentials, deliver paired pulse stimulation, and communicate with a device to display and record the motor evoked potentials and activation elicited during paired pulse stimulation. 5.    Delivery must include installation and onsite user training. Delivery time 90 days from receipt of order CONTRACTING WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME) DETERMINATION The determination by the Government to award a contract without providing for full and open competition is based upon the market research conducted. Specifically, NIDA-IRP, Neuroimaging Research Branch requires a MagVenture X100 with MagOption Magnetic Stimulator, 230V or its equal. For reference, the MagVenture X100 with MagOption Magnetic Stimulator, 230V, supporting equipment, and TMS coils meet the needs of this requirement includes the following Part Numbers (1each):  9016E0731, 9016D0031, 9016E0482, 9016E0501, and 9016B0151. The unique aspect of this TMS machine is that it provides continuous theta burst stimulation (i.e. 100% duty cycle). This continuous theta burst stimulation is required for the proposed research protocol. MagVenture is the sole manufacturer and supplier of a TMS machine that meets this required specification.  The intended source is: Magventure, Inc 2300 Lakeview Parkway, Ste 700 Alpharetta, GA 30009-9066 CLOSING STATEMENT THIS SYNOPSIS IS NOT A REQUEST FOR COMPETITIVE PROPOSALS.  However, interested parties may identify their interest and capability to respond to this notice.  Responses to this notice shall contain sufficient information to establish the interested parties’ bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.” A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government.  The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received by the closing date and time of this announcement and must reference the solicitation number.  Responses may be submitted electronically to Farrin Stanton, Contract Specialist, at Farrin.Stanton@nih.gov. US Mail and Fax responses will not be accepted.

Stand-alone High Performance Liquid Chromatography (HPLC) Electrochemical Detection (ECD)

Department of Health and Human Services, National Institutes of Health | Published August 31, 2016  -  Deadline September 7, 2016
cpvs

INTRODUCTION This is a pre-solicitation non-competitive (notice of intent) synopsis to award a contract without providing for full or open competition (including brand-name). THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR PROPOSAL. A SOLICITATION WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The National Institute on Drug Abuse (NIDA), Consolidated Station Support and Simplified Acquisitions (CSS/SA) Branch intends to negotiate and award a purchase order to Eicom USA for stand alone High Performance Liquid Chromatography Electrochemical Detecion equipment  without providing for full and open competition (including brand-name). NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE The intended procurement is classified under NAICS code 423490 with a Size Standard of 150 Employees. REGULATORY AUTHORITY The resultant contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular  (FAC) 2005-89 dated July 15, 2016. This acquisition is for a commercial item or service and is conducted under the procedures as prescribed in FAR subpart 13-Simplified Acquisition Procedures. This acquisition is NOT expected to exceed the simplified acquisition threshold STATUTORY AUTHORITY This acquisition is conducted under the authority of the authority of FAR Subpart 13.106.1.b-1 DESCRIPTION OF REQUIREMENT The National Institute on Drug Abuse (NIDA), Molecular Targets and Medications Discovery Branch, Drug Designer Research Unit requires a stand-alone High Performance Liquid Chromatography (HPLC) Electrochemical Detection (ECD) System for analyzing samples for testing newly-emerging abused drugs that pose a threat to public health. Specifically, the NIDA requires the following:   Purpose and Objectives The National Institute on Drug Abuse (NIDA), Molecular Targets and Medications Discovery Branch, Drug Designer Research Unit requires a stand-alone High Performance Liquid Chromatography (HPLC) Electrochemical Detection (ECD) System for analyzing samples for testing newly-emerging abused drugs that pose a threat to public health. Specifically, the NIDA requires the following:   The HPLC system must use electrochemical detection to provide high sensitivity.  It must be capable of 160 amol sensitivity for dopamine and serotonin and 5 fmol for acetylcholine.  Another key feature is having a spring loaded cell design which maintains proper pressure at all times.  This ensures maximum sensitivity.  The working electrode must be easily accessible so that it can be wiped clean and reinstalled to maintain sensitivity.  The system must have a small binary pump, not an HPLC pump with a pulse damper.  This allows the pressure to stabilize quickly, piston stroke speed changes to quench pulses, and cleaning is quick and easy.  The system must have ready-to-use analytical applications along with specially designed columns for ease of use.  Due to space constraints in the lab, the system must have the online degasser, HPLC pump, manual injector, column temperature controller, and electrochemical detector cell all contained in one compact unit (250 (w) x 399 (h) x 365 (d) mm/approx.).  A complete data system including software and data controller must accompany the purchase of the system to analyze the data and compile the results.  The Eicom HPLC-ECD system with Envision data system (part #: HTEC-510 and EPC-700 respectively) fulfill our requirements.  The HPLC system we would like to purchase must interface with existing equipment in the lab and Eicom is the only supplier that will work with our existing equipment.  Our current HPLC system needs to be replaced because due to its age, it is obsolete and replacement parts are difficult to get or are not available. Delivery time One month from recipt of order. CONTRACTING WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME) DETERMINATION The determination by the Government to award a contract without providing for full and open competition is based upon the market research conducted. Specifically, Eicom is the sole source provider of the requested HPLC. The intended source is: Eicom USA 7098 Miratech Drive, Suite 100 San Diego CA 92121 CLOSING STATEMENT THIS SYNOPSIS IS NOT A REQUEST FOR COMPETITIVE PROPOSALS.  However, interested parties may identify their interest and capability to respond to this notice.  Responses to this notice shall contain sufficient information to establish the interested parties’ bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.” A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government.  The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received by the closing date and time of this announcement and must reference the solicitation number.  Responses may be submitted electronically to Farrin Stanton, Contract Specialist, at Farrin.Stanton@nih.gov. US Mail and Fax responses will not be accepted.

APOMAG-62K-04

Department of Health and Human Services, National Institutes of Health | Published August 30, 2016  -  Deadline September 6, 2016
cpvs

This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation and a separate written solicitation will not be issued. This solicitation number is NICHD-16-159 and is issued as a Request for Quotation (RFQ). The solicitation/contract will include all applicable provisions and clauses in effect through Federal Acquisition Circular 2005-89. The North American Industry Classification (NAICS) Code is 334516 and the business size standard is 1000 employees. However, this solicitation is not set aside for small business. This acquisition is being conducted using Simplified Acquisition Procedures in accordance with FAR Part 13. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) intend to contract on a sole source basis with EMD Millipore Corporation of Chicago, IL to procure the following item: Product Code: APOMAG-62K-04 Human - Quantity (65) The purchase of human Apolipoprotein Mulitplex assay kits sold by the vendor, EMD-Millipore. These kits are required to perform assays for NIDDK's samples. The markers that we are required to measure are Apoliporprotein A, Apoliporprotein C, Apoliporprotein B-100 and Apoliporprotein E. EMD-Millipore is the ONLY vendor that makes this combination of analytes that can be measured using the magnetic bead multiplex kits using LuminexTM technology. Additionally, we have tested this kit using a few samples from the study to validate the assay for cross reactivity and reproducibility. A pilot study was successful and for further testing of the remaining samples in the study it is essential that we use the same type of antibody. Therefore it is crucial that we maintain the ability to order kits from this vendor.The proposed contract action is for supplies or services for which the Government intends to solicit and negotiate with only one source under authority of the 41 U.S.C. 253(c) (1), FAR 6.302. The offeror must include a completed copy of the provision of FAR Clause 52.212-3, Offeror Representations and Certifications - Commercial Items with its offer. The provisions of FAR Clause 52.212-1 Instructions to Offerors - Commercial Items; FAR Clause 52.212-2, Evaluation - Commercial Items; FAR Clause 52.212-4, Contract Terms and Conditions - Commercial Items; and FAR 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders - Commercial Items - Deviation for Simplified Acquisitions applies to this acquisition. The offeror must include their Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. The clauses are available in full text at http://www.acquisition.gov/far/. Interested vendors capable of furnishing the government with the product specified in this synopsis should submit a copy of their quotation to the below address or via email to verne.griffin@nih.gov. Offers must also be accompanied by descriptive literature, delivery timeframe, warranties and/or other information that demonstrates that the offer meets all of the foregoing requirements. Quotations will be due on September 6, 2016 before 11:00am EST. via email or postal mail. The quotation must reference "Solicitation number" NICHD-16-159. Quotations sent by postal mail or other mailing services must be submitted to the following address: Eunice Kennedy Shriver National Institute of Child Health and Human Development 6710B Rockledge Drive, Room 1155A, MSC 7000 Bethesda, MD 20892. Note: Fed Ex/Ups/other courier use 20817. Attention: Verne Griffin, by the date and time mentioned above. Any questions must be sent via email to verne.griffin@nih.gov and must include solicitation# NICHD-16-159 in the subject line of email. Faxed copies/responses will not be accepted. Note: In order to receive an award, contractor must be registered and have valid certification for all awards in the SAM database @www.sam.gov.

Custom Exendin-4 Peptide

Department of Health and Human Services, National Institutes of Health | Published August 30, 2016  -  Deadline September 6, 2016
cpvs

INTRODUCTIONTHIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Heart, Lung, and Blood Institute (NHLBI), Office of Acquisitions (OA) on behalf of the National Institute of Biomedical Imaging and Bioengineering (NIBIB), intends to negotiate and award a Purchase Order without providing for full and open competition (Including brand-name) to C S Bio, 20 Kelly CT, Menlo Park, CA 94025 for custom made Exendin-4 Peptides. NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODEThe intended procurement is classified under NAICS code 325199, All other basic organic chemical manufacturing, with a Size Standard of 1,000 employees. REGULATORY AUTHORITYThe resultant contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 05-89 effective 15 AUG 2016. This acquisition is conducted under the procedures as prescribed in FAR subpart 13-Simplified Acquisition Procedures at an amount not exceeding the simplified acquisition threshold ($150,000). STATUTORY AUTHORITY This acquisition is conducted under the authority of 41 U.S.C. 253(c) under provisions of the statutory authority of FAR Subpart FAR 6.302-1-Only one responsible source and no other supplies or services will satisfy agency requirements 41 U.S.C. 253(c)(1). DESCRIPTION OF REQUIREMENT Background The National Institutes of Health (NIH) is the nation's leading medical research agency, and the primary Federal agency conducting and supporting medical discoveries that improve people's health and save lives. The mission of the National Institute of Biomedical Imaging and Bioengineering (NIBIB) is to improve health by leading the development and accelerating the application of biomedical technologies. The Institute is committed to integrating the physical and engineering sciences with the life sciences to advance basic research and medical care. The Laboratory of Molecular Imaging and Nanomedicine (LOMIN) at NIBIB does research to identify disease-specific biomarkers, to develop new molecular imaging probes, to apply newly developed probes in multimodality imaging, and to characterize novel imaging and therapeutic agents, both in vitro and in vivo. Using a multidisciplinary approach, LOMIN builds new systems for various biomedical applications ranging from the medical use of peptide-based diagnostic agents, to therapeutic agents, and even possible future applications of theranostics (diagnosis + therapy). The LOMIN is producing Evans blue dye conjugate from custom peptides for treatment of type-2 diabetes in db/db mice and cynomolgus monkeys. The NIBIB has a requirement for more custom made Exedin-4 peptides to continue the current research. Purpose and ObjectivesThe purpose of this contract is to procure custom made Exedin-4 peptides for use in the construction of chemical analogs for testing in biological systems for imaging and therapy applications. The objective of this protocol is to continue the current research involving the peptides and scale up the synthesis and test the compound in more mice and primates to obtain statistically significant results. Project Description The contractor shall provide the following product: 1: Product name: C S BIO Exendin-4; Description: custom peptide; Quantity: 20 grams Delivery:Overnight Shipping upon receipt of awardNational Institutes of Health, NIBIB10 Center Drive Building 10Bethesda, MD 20892 CONTRACTING WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME) DETERMINATIONOnly one source is available; the determination by the Government to make a single-sole source is based upon the market research conducted as prescribed in FAR Part 10- specifically the results of the Sources Sought notice NHLBl-CSB-EB-2016-274-KEW posted 8/19/16 that C S BIO is the sole contractor capable of providing the required custom peptides, no other vendor provided a capability statement. C S Bio does not authorize 3rd party resellers to distribute the Exendin-4 Peptide, C S Bio is the sole source provider. The Peptides are unique because C S BIO customizes standard Exendin-4 Peptides by adding to the formula, the custom formula is proprietary to C S BIO. The LOMIN lab needs to continue using this formula to keep results consistent with prior year results. Use of a different formula will invalidate current research data and compromise the comparisons to prior year research. CLOSING STATEMENTThis synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received by 9/6/16 0900 EST and must reference number NHLBI-CSB-EB-2016-297-KEW. Responses may be submitted electronically to Kyle Wisor, Kyle.Wisor@nih.gov, or by U.S. mail to the National Heart, Lung, and Blood Institute, Office of Acquisitions, COAC Services Branch,6701 Rockledge Drive, Suite 6150B, Bethesda, MD 20892-7902, Attention: Kyle Wisor. Fax responses will not be accepted. "All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency."  

Acquisition of a Controllable 3-axes Precision Microscope Stage

Department of Health and Human Services, National Institutes of Health | Published August 30, 2016  -  Deadline September 9, 2016
cpvs

Contracting Office Address:Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E144, Bethesda, MD 20892, UNITED STATES Description:The National Cancer Institute (NCI), Center for Cancer Research (CCR), Laboratory of Receptor Biology and Gene Expression (LRBGE), plans to procure on a sole source basis a ASI PZ-2150-XYFT precision microscope stage that is manufactured by Applied Scientific Instrumentation, Inc. (ASI), 29391 West Enid Rd, Eugene, OR 97402. The response close date of this notice for this requirement is in accordance with FAR 5.203(a)(1). This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1), and is exempt from the requirements of FAR Part 6. The North American Industry Classification System code is 334516 and the business size standard is 1,000 employees. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The period of performance: delivery is expected within 90 days of award. It has been determined there are no opportunities to acquire green products or services for this procurement. The research program in the Laboratory of Receptor Biology and Gene Expression (LRBGE) concerns the elucidation of mechanisms involved in the regulation of genetic expression in eukaryotic cells, and the identification of genes and regulatory processes involved in modulated states of expression during oncogenesis. Particular consideration is given to the study of the steroid/thyroid/RAR superfamily of nuclear receptors (Hormone Action and Oncogenesis Section [HAO], Signal Transduction Group). A special emphasis is placed on the function of these hormone-dependent regulators in the context of chromatin and higher-order nuclear structure. The precision microscope stage will be a part of a larger optical system in the Systems Biology of Gene Expression Section in the Laboratory of Receptor Biology and Gene Expression designed to interrogate gene expression at the single molecule level in living cells. The required microscope stage must be mechanically stable for long time-lapse measurements. The stage must be able to scan the sample and return to the same position within 100 nm. The stage must be controlled on all 3-axes and have the ability to move 150 microns in the z dimension in 200 ms for fast image acquisition. The stage must be compatible with the microscope stand. There must be technical support which is readily accessible in a timely and convenient manner in Building 41. The stage must be compatible with existing microscopes in the NCI Microscopy Core Facility.The Contractor shall provide the following:One (1) - controllable 3-axes precision microscope stage including the following characteristics:• scan the sample and return to the same position within 100 nm• controlled on all 3-axes via closed-loop DC servomotors• have the ability to move 150 microns in the z dimension in 200 ms for fast image acquisition• Smooth Adjustable dual-range joystick control• stage must have compatibility with various microscope stands in the LRBGE• Wide dynamic speed range with adjustable trapezoidal move profiles DELIVERY: Contractor shall provide standard delivery of the instrument within 90 days after the award to: NIH/NCI Bethesda, Maryland 20892. Upon delivery, contractor must notify the NCI Technical Point of Contact, shown on the award, to schedule the delivery date and time. INSTALLATION: Contractor shall install the specified equipment and have ready to use within seven (7) days after delivery and acceptance.PAYMENT: Payment shall be made in arrears after delivery, installation, and upon Government acceptance of the specified equipment, and submission of an invoice to the address shown in the award pursuant to the invoicing instructions in the award. ASI utilizes a unique closed-loop design in their automated XY stages that insures extremely precise and repeatable movement. This is important for time-lapse, and other studies were open loop stepper motor systems just would not work. ASI holds US patent # 7180662 for embedding piezos within the top plate of the stage; this is critical for correct sample positioning. There are no other commercial products in this price range with the required sensitivity, resolution, speed and ability to perform specified task. There are no other vendors that guarantee compatibility, or offer ASI's patented piezo technology. This instrument is similar in operation and resolution to existing equipment in the lab, making it compatible with current laboratory protocols and service expertise. There is no other known source that specifically meets all of the stated technical and scientific requirements required by the LRGBE. This notice is not a request for competitive quotation. However, if any interested party, especially small businesses, believes it can meet the above requirement, it may submit a capability statement, proposal, or quotation, which shall be considered by the agency. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the NCI to determine if the party can perform the requirement. Responses must be received in the contracting office by 12:00PM EDT, on Sept. 9, 2016. All responses and questions must be in writing and faxed (240) 276-5401 or emailed to Catherine Muir, Contracting Officer via electronic mail at muirca@mail.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, Contractors must be registered and have valid, current Entity Record, including current Representations and Certifications, in the System for Award Management (SAM) through SAM.gov. Reference: N02RC62689-76 on all correspondence. 

Maintenance services for BD Biosciences FACSAria Fusion Special Order (SORP), two Laser System Flow Cytometry Cell Sorter, with three additional lasers, one computer workstation and the custom-tailored biosafety cabinet

Department of Health and Human Services, National Institutes of Health | Published August 30, 2016  -  Deadline September 8, 2016
cpvs

Contracting Office AddressDepartment of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E226, Bethesda, MD 20892, UNITED STATES. Non-USPS mail such as Fedex, UPS and other private carriers please use Rockville, MD 20850. This is a combined synopsis/solicitation for commercial items, prepared in accordance with format in FAR 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation and a separate written solicitation will not be issued. This solicitation: No. N02RC62635-24 includes all applicable provisions and clauses in effect through FAR FAC 2005-89 (August 2016) simplified procedures for commercial items. The North American Industry Classification System code is 811219 and the business size standard is $20.5 million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract with a base plus three option periods. I. Description of Requirement Flow cytometers are used to analyze or sort cells based on cell size, shape, internal complexity and expression of intracellular or cell surface molecules. The molecules expressed are identified by staining the cells with specific fluorescent probes or antibodies that have been linked to fluorescent dyes. Fluorescent proteins can also be introduced into the cell to identify a unique feature or function of the cell. These cells are then analyzed on a flow cytometer, in which each cell or particle in a sheath fluid stream passes one by one through one or more lasers. The fluorescently labeled cells are excited by specific lasers and emit light at various wavelengths different from the lasers themselves. Cells may be sorted into distinct cell populations when an electronic charge is applied to a drop containing the cell of interest and diverting it to a collection vessel. The Laboratory of Genome Integrity (LGI), Flow Cytometry Core Facility provides flow cytometry and cell sorting support to all the laboratories within NCI's Center for Cancer Research (CCR). These instruments provide reliable and consistent service to investigators from over 35 NCI labs and branches. Over 200 individual scientists, roughly 60 principal investigators, utilize the instruments in the LGI Flow Cytometry Core Facility annually for their experiments. The contractor shall provide all labor, material and equipment to maintain BD Biosciences FACSAria Fusion Special Order (SORP), two Laser System Flow Cytometry Cell Sorter, with three additional lasers, one computer workstation and the custom-tailored biosafety cabinet at the LGI, Flow Cytometry Core Facility. 1. FACSAria Fusion 2 Laser System - SN: P65828200015a. includes the BD FACSAria Fusion Cytometer with 2 Lasers and one computer workstation (excluding printers)2. OBIS 488-60 Blue Laser - SN: NO-SERIAL-95103. Coherent LSR OBIS 640-100 LX - SN: NO-SERIAL-95114. COMP 561-50 Lt Yellow Laser - SN: NO-SERIAL-95125. OBIS 405-50 LX Violet Laser - SN: NO-SERIAL-95136. G4 355-60 UV Laser - SN: NO-SERIAL-9514 All maintenance service shall be performed in accordance with the manufacturer's standard commercial maintenance practices. The period of performance for this contract includes a base year and three, one year options. The base contract will commence September 30, 2016 and end September 29, 2017. Option years will be as follow: Option 1 - September 30, 2017 through September 29, 2018; Option 2 - September 30, 2018 through September 29, 2019;Option 3 - September 30, 2019 through September 29, 2020 Scope of Work: Contractor to provide all labor, material and equipment to provide preventive maintenance for government-owned BD Biosciences brand FACSAria Fusion Special Order (SORP) 2 Laser System Flow Cytometry Cell Sorter, with three additional lasers, one computer workstation and the custom-tailored biosafety cabinet designed in collaboration with The Baker Company, for a 1-year base contract period with three subsequent one (1) year options. All maintenance service shall be performed in accordance with the manufacturer's standard commercial maintenance practices. Contractor to provide all computer software and firmware upgrades and perform computer hardware and software maintenance and repairs as specificed by OEM. PREVENTIVE MAINTENANCE: Contractor shall perform two (2) semi-annual preventive maintenance inspections on the instrument during the contract period. Technically qualified BD Biosciences factory-trained personnel or service providers authorized by BD Biosciences shall perform service. The service shall consist of thorough cleaning, calibration, adjusting, inspection, and testing of all equipment in accordance with the manufacturer's latest technical specifications. All equipment shall be operationally tested through at least one (1) complete operating cycle at the end of the preventive maintenance inspection to assure optimum and efficient performance. Cost for labor, travel, and two preventive maintenance kits are included. EMERGENCY SERVICE: Emergency repair services shall be provided on an unlimited basis during the term of this contract at no additional cost to the Government. Unlimited on-site service support and telephone support will be provided by the manufacturer Field Service Representative Monday through Friday (excluding federal holidays). Service request must be made the manufacturer's Technical Support Center (Monday-Friday, 8AM-12AM EST). All requests for repair will be dispatched with a 24-hour guaranteed response time. Costs for labor and travel are included. Contractor must hire or employ qualified service personnel trained in FACSAria repair and service by BD Biosciences. Contractor's must have evidence of the manufacturer's training. All primary service personnel shall have at least one backup support person with at least the same level of expertise on the equipment covered by this contract. Unlimited telephone support for instrumentation, applications, and reagents will be provided by a BD Biosciences factory-trained representative (Monday-Friday, 8AM-12AM EST). Upon receipt of notice that any part of the equipment is not functioning properly, the Contractor will furnish a qualified BD Biosciences factory-trained service representative to inspect the equipment and perform all repairs and adjustments necessary to restore the equipment to normal and efficient operating condition. Emergency service calls shall not replace the necessity for scheduled preventive maintenance. REPLACEMENT PARTS: The contractor shall furnish all required BD Biosciences replacement parts, with the exception of consumable parts. Parts shall be new BD Biosciences replacement parts or re-manufactured to original equipment specifications. This shall include all OEM proprietary parts manufactured or used by BD Biosciences, including, but not limited to special laser components, computer boards, cards and components and other instrument parts and components. SOFTWARE UPDATES/SERVICE: The contractor shall provide Software Service in accordance with the manufacturer's latest established service procedures, to include telephone access to technical support for use of program software and troubleshooting of the operating systems. The contractor shall receive advance approval for the installation of all software updates and revisions from the Government. Defective software shall be replaced under this contract. SERVICE EXCLUSIONS: The contractor shall not be responsible for any repairs necessitated by abuse, neglect, vandalism, the use of unauthorized parts or reagents, Acts of God, fire or water. These repairs shall be the subject of a separate purchase order and shall not be performed under this contract. PERIOD OF PERFORMANCE: Period of Performance shall consist of a one (1) year base period with the option for the same coverage for three (3) optional subsequent years. Base Period - September 30, 2016 to September 29, 2017Year 1 Option - September 30, 2017 to September 29, 2018Year 2 Option - September 30, 2018 to September 29, 2019Year 3 Option - September 30, 2019 to September 29, 2020 PERSONNEL QUALIFICATIONS: Personnel shall be trained by BD Biosciences, the manufacturer, in the servicing of the equipment as covered by this contract. All primary service personnel shall have at least one backup support person with at least the same level of expertise on the equipment covered by this contract. PLACE OF PERFORMANCE: Service shall be performed at the following location:Building 37, Room 600837 Convent DriveNCI, NIHBethesda, MD 20892-425 PAYMENT: Payment shall be made quarterly in arrears, as per the Invoice and Payment Provisions attached. Payment authorization requires submission and approval of invoice to the NCI COR and NIH Commercial Accounts. QUESTIONS ARE DUE: September 2, 2016 The purchase order will be awarded to the Lowest Price Technically Acceptable (LPTA). The award will be made on the basis of the lowest evaluated price of quotations meeting or exceeding the acceptability standards for the requirements/technical specifications stated above. The technical evaluation will be a determination based on information furnished by the vendor. The Government is not responsible for locating or securing any information which is not identified in the quote. The Government reserves the right to make an award without discussions. PROVISIONS AND CLAUSES: The following FAR provisions and clauses apply to this acquisition: FAR clause 52.212-1 INSTRUCTIONS TO OFFERORS-COMMERCIAL ITEMS (October 2015); FAR clause 52.212-3 OFFEROR REPRESENTATIONS AND CERTIFICATIONS-COMMERCIAL ITEMS- (April 2016) WITH DUNS NUMBER ADDENDUM {52.204-6 (July 2013)}; FAR Clause 52.212-4 CONTRACT TERMS AND CONDITIONS - COMMERCIAL ITEMS (May 2015); FAR Clause 52.212-5: CONTRACT TERMS AND CONDITIONS REQUIRED TO IMPLEMENT STATUTES OR EXECUTIVE ORDERS-COMMERCIAL ITEMS (June 2016). The following FAR clauses cited in paragraph (b) of the clause at FAR 52.212-5 are also applicable to this acquisition;FAR Clause 52.204-10 Reporting Executive Compensation and First-Tier Subcontract AwardsFAR Clause 52.209-6 Protecting the Government's Interest When Subcontracting with Contractors Debarred, Suspended, or Proposed for DebarmentFAR Clause 52.209-9 Updates of Publicly Available Information Regarding Responsibility Matters FAR Clause 52.219-4 Notice of Price Evaluation Preference for HUBZone Small Business Concerns.FAR Clause 52.219-28 Post Award Small Business Program RepresentationFAR Clause 52.222-3 Convict LaborFAR Clause 52.222-21 Prohibition of Segregated FacilitiesFAR Clause 52.222-26 Equal OpportunityFAR Clause 52.222-35 Equal Opportunity for VeteransFAR Clause 52.222-36 Equal Opportunity for Workers with Disabilities FAR Clause 52.222-37 Employment Reports on VeteransFAR Clause 52.223-18 Encouraging Contractor Policies to Ban Text Messaging while Driving FAR Clause 52.225-3 Buy American Act - Free Trade Agreements - Israeli Trade Act (Alternate II)FAR Clause 52.225-13 Restrictions on Certain Foreign PurchasesFAR Clause 52.232-33 Payment by Electronic Funds Transfer-System for Awards Management (SAM) Full text copies of the representations and certifications for other cited provisions and clauses may be obtained on line at the NCI website at http://ncioa.cancer.gov/oa-internet/ or from Kimesha Leake, Contract Specialist at Kimesha.Leake@nih.gov OFFERORS: Offers must be submitted on an SF-1449 with a completed 52.212-3 Offeror Representations and Certifications-Commercial Items-with DUNS Number Addendum, signed by an authorized representative of the offeror OR provide valid certification showing that the offeror is registered in the System for Award Management (SAM) through www.sam.gov Quotations must be received in the NCI-OA contracting office by September 8, 2016 at 4:00 pm EST. Please refer to solicitation number N02RC62635-24 on all correspondence. No collect calls or faxed quotations will not be accepted. Electronic quotations will be accepted at Kimesha.leake@nih.gov All questions shall be in writing and may be addressed to the aforementioned individual noted above. In order to receive an award, contractors must be registered and have valid certification in the System for Award Management through sam.gov.

Computational Chemistry Infrastructure Setup and Support

Department of Health and Human Services, National Institutes of Health | Published August 30, 2016  -  Deadline September 6, 2016
cpvs

INTRODUCTION This is a pre-solicitation non-competitive (notice of intent) synopsis to award a contract without providing for full or open competition (including brand-name). THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR PROPOSAL. A SOLICITATION WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The National Institute on Drug Abuse (NIDA), Consolidated Station Support and Simplified Acquisitions (CSS/SA) Branch intends to negotiate and award a purchase order to Schrodinger, LLLC  for computational chemistry infrastructure setup and support without providing for full and open competition (including brand-name). NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE The intended procurement is classified under NAICS code 511210 with a Size Standard of $38.5 million dollars . REGULATORY AUTHORITY & STATUATORY AUTHORITY The resultant contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular  (FAC) 2005-89 dated July 14, 2016. This acquisition is for a commercial item or service and is conducted under the procedures as prescribed in FAR subpart 13-Simplified Acquisition Procedures. This acquisition is NOT expected to exceed the simplified acquisition threshold. This acquisition is conducted under the authority of the authority of FAR Subpart 13.106.1.b-1 DESCRIPTION OF REQUIREMENT The mission of the Intramural Research Program (IRP) of the National Institute on Drug Abuse is to conduct state-of-the-art research on basic mechanisms that underlie drug abuse and addiction, and to develop new methods for the treatment of drug abuse and addiction.  Research is supported at the molecular, genetic, cellular, animal, and clinical levels and is conceptually integrated, highly innovative, and focused on major problems in the field.  The long-term goal of the research is to better understand the biological and behavioral factors contributing to initiation, maintenance, and elimination of drug abuse and addiction (and associated diseases), and to translate this knowledge into improved strategies for preventing, treating, and reducing the negative consequences for the individual and for society caused by drug abuse and addiction.  In order to complete the initial set-up and continued support of on-going computational research at NIDA-IRP, the CCMBU requires specific specialized software and dedicated highly skilled expertise and support of the established computational infrastructure.  Much of the initial installation and configuration required for this infrastructure has been completed.    Project Requirements: The CCMBU staff of the NIDA IRP requires the services of a state of the art modeling and simulation solutions provider in the area of structure-based drug design.  The vendor will be required to provide computational chemistry software and infrastructure maintenance and support services to the NIDA IRP computational chemistry equipment located in Baltimore Maryland.  Specifically, the NIDA IRP requires a firm with the comparable expertise to provide: 14 days of ongoing low-level systems proprietary support of the computational infrastructure over the period of one (1) year. Additionally, the firm must be an approved commercial distributor of computation software with authorization to provide the following: Desmond MD (Commercial version) OPLS3 force field (FF) FF Builder (Commercial version)   Period of Performance 12 months from notice of award CONTRACTING WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME) DETERMINATION The determination by the Government to award a contract without providing for full and open competition is based upon the market research conducted. Specifically, Schrodinger having designed and begun installation of the existing computational system, is the only vendor capable of understanding the current HPC infrastructure, and possessing the ability to provide the required software packages including a commercial application of the molecular dynamic package Desmond as well as other proprietary software packages based upon that software.  No other vendor has access to these software, making Schrodinger the only vendor capable of providing these services.   Schrodinger, LLC 101 SW Main Street, STE 1300 Portland, OR 97204-3212 CLOSING STATEMENT THIS SYNOPSIS IS NOT A REQUEST FOR COMPETITIVE PROPOSALS.  However, interested parties may identify their interest and capability to respond to this notice.  Responses to this notice shall contain sufficient information to establish the interested parties’ bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.” A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government.  The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received by the closing date and time of this announcement and must reference the solicitation number.  Responses may be submitted electronically to Farrin Stanton, Contract Specialist, at Farrin.Stanton@nih.gov. US Mail and Fax responses will not be accepted.

SERVICE CONTRACT

Department of Health and Human Services, National Institutes of Health | Published August 30, 2016  -  Deadline September 6, 2016
cpvs

This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation and a separate written solicitation will not be issued. This solicitation number is NIHNICHD2016011 and is issued as a Request for Quotation (RFQ). The solicitation/contract will include all applicable provisions and clauses in effect through Federal Acquisition Circular 2005-89. The North American Industry Classification (NAICS) Code is 811219 and the business size standard is $20500000 Million. However, this solicitation is not set aside for small business. This acquisition is being conducted using Simplified Acquisition Procedures in accordance with FAR Part 13. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) intend to contract on a sole source basis with Bruker Biospin Corporation of Billerica, MA to procure the following items: CryoPlatform w/annual maintenance AVC800 CryoPlatform w/annual maintenance AV600 CryoPlatform w/annual maintenance AVHD700X CryoPlatform w/annual maintenance AVANCE III NMR SPECTROMETERCryoPlatform w/annual maintenance AV500CryoPlatform w/annual maintenance AV600CryoPlatform w/annual maintenance AV900CryoPlatform w/annual maintenance AV600CryoPlatform w/annual maintenance AV500CryoPlatform w/annual maintenance AV500CryoPlatform w/annual maintenance AV600 The annual service and repair contract shall cover remote diagnosis of the correct functioning of Bruker CryoPlatformTM systems, and repairs if needed. All required service and repair shall be carried out by Bruker personnel specifically trained for this work, and work will be initiated within a period of two working days from the time that the vendor detects a system's malfunction, or is notified by an NIDDK staff member of a malfunction on the equipment. The contract shall cover all expenses associated with any needed repairs, including travel, parts, and labor, but not the cost of cryogens and gases.  The CryoPlatformTM cooling system incorporates pumps and compressors that require periodic maintenance. The overhaul maintenance interval for these units is once every 10,000 operating hours corresponding to about a 12 month period. The service must be performed by a trained specialist and typically takes two days. CryoPlatformTM Annual Maintenance Overhaul Description:These onetime equipment overhauls shall be performed during a scheduled visits, which accommodate the needed downtime for the overhaul. Because of the expenses involved with the cost of the Overhauling of the equipment, it is expected that this portion of the contract will be invoiced separately, after the overhauls have been performed, and the bulk expense of this portion of the contract shall be paid in a onetime, net 30 payment. This service contract shall be for 12 months from date of award and provide additional protection for unexpected repairs or malfunctions of the cryoplatforms. The NIDDK shall be afforded priority response time and a qualified Bruker technician will provide any necessary assistance onsite. The proposed contract action is for supplies or services for which the Government intends to solicit and negotiate with only one source under authority of the 41 U.S.C. 253(c) (1), FAR 6.302. The offeror must include a completed copy of the provision of FAR Clause 52.212-3, Offeror Representations and Certifications - Commercial Items with its offer. The provisions of FAR Clause 52.212-1 Instructions to Offerors - Commercial Items; FAR Clause 52.212-2, Evaluation - Commercial Items; FAR Clause 52.212-4, Contract Terms and Conditions - Commercial Items; and FAR 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders - Commercial Items - Deviation for Simplified Acquisitions applies to this acquisition. The offeror must include their Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. The clauses are available in full text at http://www.acquisition.gov/far/. Interested vendors capable of furnishing the government with the product specified in this synopsis should submit a copy of their quotation to the below address or via email to verne.griffin@nih.gov. Offers must also be accompanied by descriptive literature, delivery timeframe, warranties and/or other information that demonstrates that the offer meets all of the foregoing requirements. Quotations will be due on September 6, 2016 before 11:00am EST. via email or postal mail. The quotation must reference "Solicitation number" NIHNICHD2016011. Quotations sent by postal mail or other mailing services must be submitted to the following address: Eunice Kennedy Shriver National Institute of Child Health and Human Development 6710B Rockledge Drive, Room 1155A, MSC 7000 Bethesda, MD 20892. Note: Fed Ex/Ups/other courier use 20817. Attention: Ms. Verne Griffin, by the date and time mentioned above. Any questions must be sent via email to verne.griffin@nih.gov and must include solicitation# NIHNICHD2016011 in the subject line of email. Faxed copies/responses will not be accepted.  Note: In order to receive an award, contractor must be registered and have valid certification for all awards in the SAM database @www.sam.gov.    

Animal racking and caging system components by Thoren Caging System, Inc

Department of Health and Human Services, National Institutes of Health | Published August 30, 2016  -  Deadline September 2, 2016
cpvs

(i) This is a combined synopsis/solicitation (CSS) for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a separate written solicitation will not be issued. (ii) The solicitation number is HHS-NIH-NIDA-(SSSA)-CSS-2016-629 and the solicitation is issued as a request for quotation (RFQ). THIS IS A NON-COMPETITIVE (NOTICE OF INTENT) COMBINED SYNOPSIS SOLICITATION TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institute on Drug Abuse (NIDA), Station Support Contracts and Simplified Acquisitions Branch (SS/SA) on behalf of the National Institute of Aging (NIA) intends to negotiate and award a purchase order without providing for full and open competition (Including brand-name) to Thoren Caging System, Inc located at 815 W 7th Street, Hazelton, PA 18201 for Thoren-brand animal racking and caging system components for existing equipment at the National Institute ofAging (NIA). This acquisition is conducted as non-competitive for a commercial item or service and is conducted under the authority of the FAR Subpart 13.5-Simplified Procedures for Certain Commercial Items and 13.501 Special documentation requirements and the authority of 41 U.S.C. 1901 and the statutory authority of FAR 6.302-1 Only one responsible source and no other supplies or services will satisfy agency requirements. Pursuant to FAR Subpart 13.501 (a) (1) (iii) the justification (excluding brand name) will be made available within 14 days after contract award or in the case of unusual and compelling urgency within 30 days after contract award. Pursuant to FAR Subpart 13.501 (a) (1) (iv) the rationale for the brand name justification is based upon market research that Thoren Caging System, Inc. is the only known source that can fully achieve the subject government requirement. Market research was obtained through Sources Sought notice No. HHS-NIH-NIDA-SSSA-SS-2016-561 published in FedBizOpps from July 21, 2016 through August 1, 2016. (iii.) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular Number / Effective Date: FAC 2005-89 / 07-14-2016. (iv.) The North American Industry Classification System (NAICS) code for this procurement is 339999 - All other Miscellaneous Manufacturing with associated business size standard 500 employees.(v.) Thoren Caging System, Inc -brand supply: CG05B01 Model# 5 Expanded Small Mouse Cage, Udel, quantity 2000; FC05DHN Filter cover# 5 Udel, with handle, slot and Reemay to fit# 5, 15 or 7 cages, quantity 2000. (vi.) Purchase description: The purpose of this acquisition is to obtain Thoren Caging System brand supply interconnect with existing Thoren cage systems in use with racks, cages and blower units. Subject supply shall be used by the Comparative Medicine Section (CMS) at the National Institute of Aging (NIA) under the NIA Office of the Scientific Director (OSD). Subject supply shall replace worn and broken rack and caging components contained in existing rodent racking systems that house the NINCMS research rodent colony. The existing racks and caging system is manufactured by and previously purchased from Thoren Caging Systems, Inc. These replacement parts and equipment are essential to maintain animal racking systems currently in use at the NINCMS. (vii) The anticipated delivery date is three (3) months after receipt of an order with delivery, inspection and acceptance performed at a Government facility located at 251 Bayview Blvd, Baltimore, MD21224. (viii) The provision at FAR clause 52.212-1, Instructions to Offerors - Commercial Items, applies to this acquisition. (ix) The provision at FAR clause 52.212-2, Evaluation - Commercial Items, applies to this acquisition. (a) The Government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation will be most advantageous to the Government, price and other factors considered. Evaluation factors that will be used to evaluate the offer most advantageous to the Government, price and other factors considered, include: (1) ability to meet the technical requirements stated in this presolicitation, (2) Past Performance: The offeror must submit with their proposal a list of the last three (3) contracts completed during the past two (2) years and / or contracts awarded currently in process that are similar in nature to the work scope. Contracts listed may include those entered into by the Federal Government, agencies of state and local governments and commercial concerns. Newly formed entities without prior contracts should list contracts and subcontracts as required above for all key personnel. For each contract, subcontract, or reference include: (i) Name of Contracting Organization; (ii) Contract Number (for subcontracts, provide the prime contract number and the subcontract number); (iii) Contract Type; (iv) Total Contract Value; (v) Description of Requirement;(vi) Contracting Officer's Name and Telephone Number; (vii) Program Manager's Name and Telephone Number; and (viii) North American Industry Classification System (NAICS) Code. The Government is not required to contact all references provided by the offeror. (3) Price. The Government will evaluate offers for award purposes by making a price reasonableness determination. Offerors must submit historical pricing information essentially equal to a commercial item price list containing the price offered for the subject supply. Technical and past performance, when combined, are significantly more important than cost or price. (b) Options. The Government will evaluate offers for award purposes by adding the total price for all options to the total price for the basic requirement. The Government may determine that an offer is unacceptable if the option prices are significantly unbalanced. Evaluation of options shall not obligate the Government to exercise the option(s). (c) A written notice of award or acceptance of an offer, mailed or otherwise furnished to the successful offeror within the time for acceptance specified in the offer, shall result in a binding contract without further action by either party. Before the offer's specified expiration time, the Government may accept an offer (or part of an offer), whether or not there are negotiations after its receipt, unless a written notice of withdrawal is received before award. (x) The Offerors to include a completed copy of the provision at FAR clause 52.212-3, Offeror Representations and Certifications-Commercial Items, with its offer. (xi) The FAR clause at 52.212-4, Contract Terms and Conditions - Commercial Items, applies to this acquisition. (xii) FAR clause at 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders-Commercial Items, applies to this acquisition. Specifically, 52.232-33, Payment by Electronic Funds Transfer-System for Award Management (Jul 2013) applies to this acquisition. (xiv) The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement. (xv) Responses to this solicitation must include sufficient information to establish the interested parties' bona-fide capabilities of providing the product or service. The price quote shall include: unit price, list price, shipping and handling costs, delivery days after contract award, delivery terms, prompt payment discount terms, F.O.B. Point (Destination or Origin), product or catalog number(s); product description; and any other information or factors that may be considered in the award decision. Such factors may include: past performance; special features required for effective program performance; trade-in considerations; probable life of the item selected as compared with that of a comparable item; warranty considerations; maintenance availability; and environmental and energy efficiency considerations. Respondents that believe that they are manufacturers or authorized resellers of the brand-name product specified in this announcement must provide, as part of their response: (a) product, catalog, model, and/or part number(s); (b) product description; (c) all relevant information and documentation that the item(s) offered meets the salient physical, functional, or performance characteristics as specified in the purchase description; quantity; estimated price or cost; shipping, handling, and/or installation charges; and delivery date after receipt of order. In addition the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." All responses must be received no later than the closing date and time specified in this announcement and reference number HHS-NIH-NIDA-SSSA-CSS-2016-629. Responses may be submitted electronically to hunter.tjugum@nih.gov and NIDASSSAPurchaseRequ@mail.nih.gov. Fax responses will not be accepted. (xvi) The name and telephone number of the individual to contact for information regarding the solicitation is Hunter Tjugum, Contract Specialist, at 301-827-5304.

Protein quantification kits and reagent supplies by Meso Scale Diagnostics

Department of Health and Human Services, National Institutes of Health | Published August 30, 2016  -  Deadline September 2, 2016
cpvs

(i) This is a combined synopsis/solicitation (CSS) for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a separate written solicitation will not be issued. (ii) The solicitation number is HHS-NIH-NIDA-(SSSA)-CSS-2016-627 and the solicitation is issued as a request for quotation (RFQ). THIS IS A NON-COMPETITIVE (NOTICE OF INTENT) COMBINED SYNOPSIS SOLICITATION TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institute on Drug Abuse (NIDA), Station Support Contracts and Simplified Acquisitions Branch (SS/SA) on behalf of the National Institute of Aging (NIA) intends to negotiate and award a purchase order without providing for full and open competition (Including brand-name) to Meso Scale Diagnostics located at 1601 Research Blvd, Rockville, MD 20850 for protein quantification kits and reagent supplies brand name only for Meso Scale Diagnostics for the National Institute of Aging (NIA). This acquisition is conducted as non-competitive for a commercial item or service and is conducted under the authority of the FAR Subpart 13.5-Simplified Procedures for Certain Commercial Items and 13.501 Special documentation requirements and the authority of 41 U.S.C. 1901 and the statutory authority of FAR 6.302-1 Only one responsible source and no other supplies or services will satisfy agency requirements. Pursuant to FAR Subpart 13.501 (a) (1) (iii) the justification (excluding brand name) will be made available within 14 days after contract award or in the case of unusual and compelling urgency within 30 days after contract award. Pursuant to FAR Subpart 13.501 (a) (1) (iv) the rationale for the brand name justification is based upon market research that Meso Scale Diagnostics is the only known source that can fully achieve the subject government requirement. Market research was obtained through Sources Sought notice No. HHS-NIH-NIDA-SSSA-SS-2016-562 published in FedBizOpps from July 21, 2016 through August 1, 2016. (iii.) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular Number / Effective Date: FAC 2005-89 / 07-14-2016. (iv.) The North American Industry Classification System (NAICS) code for this procurement is 334516 Analytical Laboratory Instrument Manufacturing with size standard 1000 employees. (v.) Meso Scale Diagnostics brand- Phospho-IRS-1 (Ser312) Whole Cell Lysate Kit (5 Pl), QTY. 3; Phospho-Tau Kit (20 Plate), QTY. 1; V-PLEX Human Total Tau Kit (5 Plate), QTY. 3; MULTI-SPOT® 96 HB 4-Spot Custom phospho Tau (181), QTY. 22; MULTl-SPOT® 96 4-Spot Custom_phospho IRS-I, QTY. 22. (vi.) Purchase description: The purpose of this acquisition is to obtain Meso Scale brand supply for existing and future research support purposes. The LN has embarked on research that isolates exosomes enriched for neuronal origin for the study of neurodegenerative disease. LN has a requirement for a supply of regents and kits to be used on existing or recent research using protein quantification aspects from Meso Scale Diagnostics. (vii) The anticipated delivery date will be after receipt of an order with delivery, inspection and acceptance at 251 Bayview Blvd, Baltimore, MD 21224. (viii) The provision at FAR clause 52.212-1, Instructions to Offerors - Commercial Items, applies to this acquisition. (ix) The provision at FAR clause 52.212-2, Evaluation - Commercial Items, applies to this acquisition. (a) The Government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation will be most advantageous to the Government, price and other factors considered. Evaluation factors that will be used to evaluate the offer most advantageous to the Government, price and other factors considered, include: (1) ability to meet the technical requirements stated in this presolicitation, (2) Past Performance: The offeror must submit with their proposal a list of the last three (3) contracts completed during the past two (2) years and / or contracts awarded currently in process that are similar in nature to the work scope. Contracts listed may include those entered into by the Federal Government, agencies of state and local governments and commercial concerns. Newly formed entities without prior contracts should list contracts and subcontracts as required above for all key personnel. For each contract, subcontract, or reference include: (i) Name of Contracting Organization; (ii) Contract Number (for subcontracts, provide the prime contract number and the subcontract number); (iii) Contract Type; (iv) Total Contract Value; (v) Description of Requirement;(vi) Contracting Officer's Name and Telephone Number; (vii) Program Manager's Name and Telephone Number; and (viii) North American Industry Classification System (NAICS) Code. The Government is not required to contact all references provided by the offeror. (3) Price. The Government will evaluate offers for award purposes by making a price reasonableness determination. Offerors must submit historical pricing information essentially equal to a commercial item price list containing the price offered for the subject supply. Technical and past performance, when combined, are significantly more important than cost or price. (b) Options. The Government will evaluate offers for award purposes by adding the total price for all options to the total price for the basic requirement. The Government may determine that an offer is unacceptable if the option prices are significantly unbalanced. Evaluation of options shall not obligate the Government to exercise the option(s). (c) A written notice of award or acceptance of an offer, mailed or otherwise furnished to the successful offeror within the time for acceptance specified in the offer, shall result in a binding contract without further action by either party. Before the offer's specified expiration time, the Government may accept an offer (or part of an offer), whether or not there are negotiations after its receipt, unless a written notice of withdrawal is received before award. (x) The Offerors to include a completed copy of the provision at FAR clause 52.212-3, Offeror Representations and Certifications-Commercial Items, with its offer. (xi) The FAR clause at 52.212-4, Contract Terms and Conditions - Commercial Items, applies to this acquisition. (xii) FAR clause at 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders-Commercial Items, applies to this acquisition. Specifically, 52.232-33, Payment by Electronic Funds Transfer-System for Award Management (Jul 2013) applies to this acquisition. (xiv) The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement. (xv) Responses to this solicitation must include sufficient information to establish the interested parties' bona-fide capabilities of providing the product or service. The price quote shall include: unit price, list price, shipping and handling costs, delivery days after contract award, delivery terms, prompt payment discount terms, F.O.B. Point (Destination or Origin), product or catalog number(s); product description; and any other information or factors that may be considered in the award decision. Such factors may include: past performance; special features required for effective program performance; trade-in considerations; probable life of the item selected as compared with that of a comparable item; warranty considerations; maintenance availability; and environmental and energy efficiency considerations. Respondents that believe that they are manufacturers or authorized resellers of the brand-name product specified in this announcement must provide, as part of their response: (a) product, catalog, model, and/or part number(s); (b) product description; (c) all relevant information and documentation that the item(s) offered meets the salient physical, functional, or performance characteristics as specified in the purchase description; quantity; estimated price or cost; shipping, handling, and/or installation charges; and delivery date after receipt of order. In addition the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." All responses must be received no later than the closing date and time specified in this announcement and reference number HHS-NIH-NIDA-SSSA-CSS-2016-627. Responses may be submitted electronically to hunter.tjugum@nih.gov and NIDASSSAPurchaseRequ@mail.nih.gov. Fax responses will not be accepted. (xvi) The name and telephone number of the individual to contact for information regarding the solicitation is Hunter Tjugum, Contract Specialist, at 301-827-5304.

Deltavision Restoration Microscopy System Upgrade

Department of Health and Human Services, National Institutes of Health | Published August 30, 2016  -  Deadline September 2, 2016
cpvs

(i) This is a combined synopsis/solicitation (CSS) for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a separate written solicitation will not be issued. (ii) The solicitation number is HHS-NIH-NIDA-(SSSA)-CSS-2016-632 and the solicitation is issued as a request for quotation (RFQ). THIS IS A NON-COMPETITIVE (NOTICE OF INTENT) COMBINED SYNOPSIS SOLICITATION TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institute on Drug Abuse (NIDA), Station Support Contracts and Simplified Acquisitions Branch (SS/SA) on behalf of the National Institute of Aging (NIA) intends to negotiate and award a purchase order without providing for full and open competition (Including brand-name) to GE Healthcare Bio-Sciences Corp. located at 100 Results Way, Marlborough, MA 01752 for an upgrade to an existing Deltavision Image Acquisition and Restoration Microscopy system, manufactured by and previously purchased from Applied Precision Instruments, for the National Institute of Aging (NIA). This acquisition is conducted as non-competitive for a commercial item or service and is conducted under the authority of the FAR Subpart 13.5-Simplified Procedures for Certain Commercial Items and 13.501 Special documentation requirements and the authority of 41 U.S.C. 1901 and the statutory authority of FAR 6.302-1 Only one responsible source and no other supplies or services will satisfy agency requirements. Pursuant to FAR Subpart 13.501 (a) (1) (iii) the justification (excluding brand name) will be made available within 14 days after contract award or in the case of unusual and compelling urgency within 30 days after contract award. Pursuant to FAR Subpart 13.501 (a) (1) (iv) the rationale for the brand name justification is based upon market research that GE Healthcare is the only known source that can fully achieve the subject government requirement. Market research was obtained through Sources Sought notice No. HHS-NIH-NIDA-SSSA-SS-2016-554 published in FedBizOpps from July 20, 2016 through August 1, 2016. (iii.) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular Number / Effective Date: FAC 2005-89 / 07-14-2016. (iv.) The North American Industry Classification System (NAICS) code for this procurement is 334516 Analytical Laboratory Instrument Manufacturing with size standard 500 employees. (v.) DeltaVision Restoration Microscopy System Upgrade to include DeltaVision upgrade components consisting of PN 29117727 Upgrade Auto FL with USB IC/IMIC (qty 2); PN 53-852056-002 Insight SSI 7 -Color Mixed for IX71 Pef Upg's; PN 53-852138-001 Microtitre stage, Field Upgrade; PN 43-406031-004 Vibration isolator Bearing 37-75 Lbs; PN 53-8511861-012 Env Ctrl uTitre Tran (120V) Clear. (vi.) Purchase description: The NIA Intramural Research Program (IRP) currently owns and operates a Deltavision Image Acquisition and Restoration Microscopy system. This system generates high resolution 3 dimensional images of tissues, cells and chromosome spreads. The IRP requires the legacy Deltavision RT system to be upgraded to allow the instrument to be a continued source of primary data. This requirement shall obtain technology that enables precise stage positioning as well as deconvolution software to the subject equipment that will allow for high-resolution imaging in low-light. Therefore, this will make the instrument capable of high-resolution low-light 3D microscopy, and will upgrade the stage to accept microtiter plates as this is an increasingly common sample format for multiplexed experiments. Minimum acceptable standards include 1. Accuracy of resampling must be (vii) The anticipated delivery date will be 8 weeks after receipt of an order with delivery, inspection and acceptance at 251 Bayview Blvd, Baltimore, MD 21224. (viii) The provision at FAR clause 52.212-1, Instructions to Offerors - Commercial Items, applies to this acquisition. (ix) The provision at FAR clause 52.212-2, Evaluation - Commercial Items, applies to this acquisition. (a) The Government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation will be most advantageous to the Government, price and other factors considered. Evaluation factors that will be used to evaluate the offer most advantageous to the Government, price and other factors considered, include: (1) ability to meet the technical requirements stated in this presolicitation, (2) Past Performance: The offeror must submit with their proposal a list of the last three (3) contracts completed during the past two (2) years and / or contracts awarded currently in process that are similar in nature to the work scope. Contracts listed may include those entered into by the Federal Government, agencies of state and local governments and commercial concerns. Newly formed entities without prior contracts should list contracts and subcontracts as required above for all key personnel. For each contract, subcontract, or reference include: (i) Name of Contracting Organization; (ii) Contract Number (for subcontracts, provide the prime contract number and the subcontract number); (iii) Contract Type; (iv) Total Contract Value; (v) Description of Requirement;(vi) Contracting Officer's Name and Telephone Number; (vii) Program Manager's Name and Telephone Number; and (viii) North American Industry Classification System (NAICS) Code. The Government is not required to contact all references provided by the offeror. (3) Price. The Government will evaluate offers for award purposes by making a price reasonableness determination. Offerors must submit historical pricing information essentially equal to a commercial item price list containing the price offered for the subject supply. Technical and past performance, when combined, are significantly more important than cost or price. (b) Options. The Government will evaluate offers for award purposes by adding the total price for all options to the total price for the basic requirement. The Government may determine that an offer is unacceptable if the option prices are significantly unbalanced. Evaluation of options shall not obligate the Government to exercise the option(s). (c) A written notice of award or acceptance of an offer, mailed or otherwise furnished to the successful offeror within the time for acceptance specified in the offer, shall result in a binding contract without further action by either party. Before the offer's specified expiration time, the Government may accept an offer (or part of an offer), whether or not there are negotiations after its receipt, unless a written notice of withdrawal is received before award. (x) The Offerors to include a completed copy of the provision at FAR clause 52.212-3, Offeror Representations and Certifications-Commercial Items, with its offer. (xi) The FAR clause at 52.212-4, Contract Terms and Conditions - Commercial Items, applies to this acquisition. (xii) FAR clause at 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders-Commercial Items, applies to this acquisition. Specifically, 52.232-33, Payment by Electronic Funds Transfer-System for Award Management (Jul 2013) applies to this acquisition. (xiv) The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement. (xv) Responses to this solicitation must include sufficient information to establish the interested parties' bona-fide capabilities of providing the product or service. The price quote shall include: unit price, list price, shipping and handling costs, delivery days after contract award, delivery terms, prompt payment discount terms, F.O.B. Point (Destination or Origin), product or catalog number(s); product description; and any other information or factors that may be considered in the award decision. Such factors may include: past performance; special features required for effective program performance; trade-in considerations; probable life of the item selected as compared with that of a comparable item; warranty considerations; maintenance availability; and environmental and energy efficiency considerations. Respondents that believe that they are manufacturers or authorized resellers of the brand-name product specified in this announcement must provide, as part of their response: (a) product, catalog, model, and/or part number(s); (b) product description; (c) all relevant information and documentation that the item(s) offered meets the salient physical, functional, or performance characteristics as specified in the purchase description; quantity; estimated price or cost; shipping, handling, and/or installation charges; and delivery date after receipt of order. In addition the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." All responses must be received no later than the closing date and time specified in this announcement and reference number HHS-NIH-NIDA-SSSA-CSS-2016-632. Responses may be submitted electronically to hunter.tjugum@nih.gov and NIDASSSAPurchaseRequ@mail.nih.gov. Fax responses will not be accepted. (xvi) The name and telephone number of the individual to contact for information regarding the solicitation is Hunter Tjugum, Contract Specialist, at 301-827-5304.

DICER I Genetic Synopsis/ Solicitation

Department of Health and Human Services, National Institutes of Health | Published September 1, 2016  -  Deadline September 7, 2016
cpvs

Contracting Office AddressDepartment of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E226, Bethesda, MD 20892, UNITED STATES. Non-USPS mail such as Fedex, UPS and other private carriers please use Rockville, MD 20850. The National Cancer Institute (NCI), Clinical Genetics Branch (CGB) would like to procure on a Brand Name or Equal basis genetic testing of DICER I.This is a combined synopsis/solicitation for commercial items, prepared in accordance with format in FAR 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation and a separate written solicitation will not be issued. This solicitation: No. N02RC62674-36 includes all applicable provisions and clauses in effect through FAR FAC 2005-88 (May 2016) simplified procedures for commercial items. The North American Industry Classification System code is 621511 and the business size standard is $32,500,000. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. I. Description of Requirement The overall study objective is to study the patterns and determinants (clinical, genetic and environmental) of the cancers which occur in persons carrying alterations in DICER1. It is anticipated that information derived from this project will provide important new information on the pathogenesis of these specific malignancies. The specific objective of this procurement is to obtain the results of DICER1 genetic testing in order to confirm or refute the diagnosis of the DICER1 syndrome in study participants, and thus classify participants properly.TASKS a. The contractor will receive samples (blood or saliva) for DICER1 genetic testing. If the contractor is blinded to identifying information pertaining to the individuals from whom these specimens were derived, the Contractor will be prohibited from seeking such information. Therefore, from the Contractor's perspective, those samples shall be anonymous.b. The Contractor must be a CLIA‐certified laboratory, so that the results can be conveyed to the patient for use in clinical management.c. The specimens will consist of peripheral blood or saliva, collected using standard methods.d. The Contractor will extract DNA from the provided samples.e. The DNA derived from these samples will be analyzed for DICER1 sequence variants in all coding exons, +/- 10 basepairs of adjacent intronic sequence and select non-coding variants. Appropriate "next-generation" sequencing (NGS) technology will be used. In addition, deletion/duplication analysis using NGS will be used. Mean coverage depth of 350X is needed, which will ensure a minimum of 50X across all variants. Variants classified as pathogenic or likely pathogenic will be confirmed with orthogonal methods.'f. The Contractor will provide a written report for each patient, noting patient name and methods used in the assay, and other CLIA-required documentation. A table of DICER1 variants found will be provided with a determination of pathogenicity, including allele frequency in appropriate control populations. Previous published reports on discovered variants in the biomedical literature will be noted. For missense and splice variants, bioinformatic predictions of pathogenicity will be provided. The presence or absence of a pathogenic variant will be clearly stated in the report.g. The written report for DICER1 genetic test results will be returned to CGB investigators within twenty-one (21) working days from specimen receipt, except in the case of unusual problems requiring additional investigation. The exceptions must be negotiated directly via telephone discussion with the CGB investigator.h. In lieu of progress meetings, CGB will discuss any unusual results on a case-by-case basis. II. Delivery: Reports. The individual patient reports must include the CGB identificationnumber and/or patient name, the Contractor's sample identification number, date sample obtained, date received in laboratory, and presumed diagnosis. III Payment: The number of samples will be indefinite delivery indefinite quantity (IDIQ). Theminimum quantity is one (1) and the maximum quantity is one hundred and twenty five (125) DICER1 tests during the period of performance of the IDIQcontract. Payment will be made in arrears after receipt and acceptance ofrequested tasks. QUESTIONS ARE DUE: September 2, 2016 The purchase order will be awarded to the Lowest Price Technically Acceptable (LPTA). The award will be made on the basis of the lowest evaluated price of quotations meeting or exceeding the acceptability standards for the requirements/technical specifications stated above. The technical evaluation will be a determination based on information furnished by the vendor. The Government is not responsible for locating or securing any information which is not identified in the quote. The Government reserves the right to make an award without discussions. PROVISIONS AND CLAUSES: The following FAR provisions and clauses apply to this acquisition: FAR 52.211-6 Brand Name or Equal. (Aug 1999) (a) If an item in this solicitation is identified as "brand name or equal," the purchase description reflects the characteristics and level of quality that will satisfy the Government's needs. The salient physical, functional, or performance characteristics that "equal" products must meet are specified in the solicitation (b) To be considered for award, offers of "equal" products, including "equal" products of the brand name manufacturer, must- (1) Meet the salient physical, functional, or performance characteristic specified in this solicitation; (2) Clearly identify the item by- (i) Brand name, if any; and (ii) Make or model number; (3) Include descriptive literature such as illustrations, drawings, or a clear reference to previously furnished descriptive data or information available to the Contracting Officer; and (4) Clearly describe any modifications the offeror plans to make in a product to make it conform to the solicitation requirements. Mark any descriptive material to clearly show the modifications (c) The Contracting Officer will evaluate "equal" products on the basis of information furnished by the offeror or identified in the offer and reasonably available to the Contracting Officer. The Contracting Officer is not responsible for locating or obtaining any information not identified in the offer (d) Unless the offeror clearly indicates in its offer that the product being offered is an "equal" product, the offeror shall provide the brand name product referenced in the solicitation. 52.212-1 Instructions to Offerors Commercial Items (APR 2014); 52.212-2 Evaluation Commercial Items (OCT 2014): FAR clause 52.212-3 OFFEROR REPRESENTATIONS AND CERTIFICATIONS-COMMERCIAL ITEMS- (March 2015) WITH DUNS NUMBER ADDENDUM {52.204-6 (July 2013)}; FAR Clause 52.212-4 CONTRACT TERMS AND CONDITIONS - COMMERCIAL ITEMS (December 2014); FAR Clause 52.212-5: CONTRACT TERMS AND CONDITIONS REQUIRED TO IMPLEMENT STATUTES OR EXECUTIVE ORDERS-COMMERCIAL ITEMS (March 2015). The following FAR clauses cited in paragraph (b) of the clause at FAR 52.212-5 are also applicable to this acquisition; FAR Clause 52.203-6, Restrictions on Subcontractor Sales to the Government (Sept 2006) FAR Clause 52.204-10, Reporting Executive Compensation and First-Tier Subcontract Awards (Oct 2015) FAR Clause 52.209-6, Protecting the Government's Interest When Subcontracting with Contractors Debarred, Suspended, or Proposed for Debarment. (Oct 2015) FAR Clause 52.219-4, Notice of Price Evaluation Preference for HUBZone Small Business Concerns (Oct 2014) FAR Clause 52.219-6, Notice of Total Small Business Aside (Nov 2011) (15 U.S.C. 644) FAR Clause 52.219-28, Post Award Small Business Program Representation (Jul 2013) FAR Clause 52.222-3, Convict Labor (June 2003) FAR Clause 52.222-19, Child Labor-Cooperation with Authorities and Remedies (Feb 2016) FAR Clause 52.222-21, Prohibition of Segregated Facilities (Apr 2015) FAR Clause 52.222-26, Equal Opportunity (Apr 2015) FAR Clause 52.222-35, Equal Opportunity for Veterans (Oct 2015) FAR Clause 52.222-36, Equal Opportunity for Workers with Disabilities (Jul 2014) FAR Clause 52.222-37, Employment Reports on Veterans (Feb 2016) FAR Clause 52.222-40, Notification of Employee Rights Under the National Labor Relations Act (Dec 2010) FAR Clause 52.223-18, Encouraging Contractor Policies to Ban Text Messaging While Driving (AUG 2011) FAR Clause 52.225-1, Buy American Act--Supplies (May 2014) FAR Clause 52.225-3, Buy American-Free Trade Agreements-Israeli Trade Act (May 2014)Alternate II (May 2014) of 52.225-3 FAR Clause 52.225-13, Restrictions on Certain Foreign Purchases (June 2008) FAR Clause 52.232-33, Payment by Electronic Funds Transfer-System for Award Management (Jul 2013) Full text copies of the representations and certifications for other cited provisions and clauses may be obtained online at the NCI website at http://ncioa.cancer.gov/oa-internet/ or from David Romley, Contract Specialist at David.Romley@nih.gov. OFFERORS: Offers must be submitted on an SF-1449 with a completed 52.212-3 Offeror Representations and Certifications-Commercial Items-with DUNS Number Addendum, signed by an authorized representative of the offeror OR provide a copy of the valid certification registrations of the offeror's Central Contractor Registration (CCR) and Online Representations and Certifications Applications (ORCA) through www.sam.gov. Quotations must be received in the NCI-OA contracting office by 12:00 p.m. EST on September 7, 2016. Please refer to solicitation number N02RC62674-36 on all correspondence. Faxed quotations will NOT be accepted. Quotations may be submitted via email to David Romley, Contract Specialist at David.Romley@nih.gov All questions shall be in writing and may be addressed to the aforementioned individual noted above. In order to receive an award, contractors must be registered and have valid certification in the System for Award Management through sam.gov.  

Brand name Laser Alignment System DORADO nova 3 green wall laser system, or equal. SB Set-Aside

Department of Health and Human Services, National Institutes of Health | Published September 1, 2016  -  Deadline September 6, 2016
cpvs

Contracting Office AddressDepartment of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E136, Rockville, MD 20850, UNITED STATES. Description The National Institutes of Health (NIH), National Cancer Institute (NCI), Center for Cancer Research (CCR), intends to procure one (1) brand name Laser Alignment System DORADO nova 3 green wall laser system, or equal. This is a combined synopsis/solicitation for commercial items, prepared in accordance with format in FAR 12.6 as supplemented with additional information included in this notice and under the authority to use simplified procedures for commercial requirements as provided in FAR 13.106. This announcement constitutes the only solicitation and a separate written solicitation will not be issued. This solicitation: No. N02CO62696-78 includes all applicable provisions and clauses in effect through FAR FAC 2005-89 (August 15, 2016). This is a small business set-aside. The North American Industry Classification System code is 334516 and the business size standard is 1000 employees. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. See attached Combined Synopsis / Solicitation for more information.

Gazetracker

Department of Health and Human Services, National Institutes of Health | Published September 12, 2016  -  Deadline September 16, 2016
cpvs

INTRODUCTION This is a pre-solicitation non-competitive (notice of intent) synopsis to award a contract without providing for full or open competition (including brand-name). THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR PROPOSAL. A SOLICITATION WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The National Institute on Drug Abuse (NIDA), Consolidated Station Support and Simplified Acquisitions (CSS/SA) Branch intends to negotiate and award a purchase order to Ryklin Software, Inc for a Gaze tracker without providing for full and open competition (including brand-name). NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE The intended procurement is classified under NAICS code 334519 with a Size Standard of 500 employees. REGULATORY AUTHORITY & STATUATORY AUTHORITY The resultant contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular  (FAC) 2005-89 dated July 14, 2016. This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures; FAR Subpart 13.5- Simplified Procedures for Certain Commercial Items; and FAR Part 12-Acquisition of Commercial Items, and IS expected to exceed the simplified acquisition threshold. DESCRIPTION OF REQUIREMENT control and data acquisition software suite, and the transition to and further development of MonkeyLogic experimental control and data acquisition software.   The maintenance component the requested is to make NIMH Cortex, originally a DOS program, operate smoothly and reliably under the Windows 7 operating system. Over the past two years, much of work has been done to achieve Windows 7 compatibility. The is still some work is to complete Windows 7 capability for both 32-bit and 64-bit installations and to finish building the testing tools so that NIMH Cortex can be compiled using the latest Microsoft software development environment.   The development component of the requested  is to extend the compatibilities of MonkeyLogic (ML) (http://www.brown.edu/Research/monkeylogic/) to support the hardware and software that are essential to many of the current NIMH Cortex users.    Because both NIMH Cortex and MonkeyLogic collect data and respond to recorded events within real-time requirements, the task of expanding MonkeyLogic is a challenging and delicate one that requires expertise at enough levels to assure safe and reliable program performance. Thus, another requirement is the development of reliable and robust performance that will not put the data acquired by monkey laboratories at risk for errors.  This past year major steps have been taken support functionality for a primate touchscreen interface, and beta testing has begun with ~5 laboratories (McGill, Vanderbilt, Mount Sinai, Oxford, and NYU). This work also facilitates the integration of additional digital input devices such as joysticks, modern eye trackers, and other instruments that transmit their signal over USB.  Significant upgrades to the video stimulus rendering system have been made.   The low-level data acquisition system within ML has been completely rebuilt. As with graphics, data acquisition, has been brought up to date and as a result is significantly faster, samples from a wider array of DAQ devices, and is far less expensive for new users to setup. Our latest release of ML has cut the cost of hardware dramatically thanks to the new "NIMH DAQ toolbox" by as much as 33% by eliminating the need for 2x daq cards and Matlab daq toolbox licensing fees. All ML source code modifications along with documentation, have been incrementally posted online in an open source repository called GitHub.com. Specifically, the url of our repository is: https://github.com/ryklin/MonkeyLogic_stable. This makes it simple for users and developers to review, contribute, clone, and use the program. The official MonkeyLogic website's download page now directs users to download exclusively and directly from this repository, making it the official distribution. Develop and maintain a user support forum to exclusively handle MonkeyLogic users:   There are 87 Members registered, consisting of at least 22 unique laboratories in the United States. There have been 529 posts in a little over a year.  This compliments the previous user forum exclusively for NIMH-Cortex users, which also has about the same (78) registered members. This allows the programmer to prioritize bug reports and focus on any major concerns addressed by existing users. Identify and fix improper program operation (bugs) using both software and hardware techniques while maintaining a bug tracking database:   We have started identifying beta testers for the last releases of ML. Testing will identify inconsistencies in the operation of the newest versions. These bugs will be the basis of a work-prioritized list of issues based on impact and frequency. Clearly identified issues will be studied and fixed. After each bug fix release, the software will be returned to the beta testers for approval. New releases of the software will require additional testing and final approval from the project manager (Dr. Mitz). Document all changes both internally (within the programming code) and in user documentation: ML programs are documented internally using best practices of the industry. User documentation will be maintained in both manual and web site formats. Major new features will be advertised in emails and posted on the web site. A history of changes will be maintained. New support programs will be documented either by adding chapters to existing manuals or through the introduction of new manuals. All manuals will be posted on the documentation page of the web site. Version information will be explicitly indicated on each manual as it is updated. Maintain open source code and use a modern source code repository:  All source code for NIMH Cortex and ML must be openly available. Development must be done using a source code repository that permits tracking development. Support for new device drivers:   Over the past several years the number of hardware cards supported by NIMH Cortex has been expanded through the software developments.  This contract requires continued support of these new drivers.  Drivers must not interfere with the real-time performance of the experimental control or data acquisition operations. Drivers will not interfere with the stability of the operating system (DOS or Windows).  Drivers must continue to operate under a wide range of conditions to validate their performance. Provide user technical support by web, email and telephone:  User technical support is a key requirement.  Technical support will be in the form of web support on the NIMH Cortex and ML web site, answering questions and collecting bug reports. Technical support will also be in the form of email, and, when necessary, telephone (or voice over IP) support. Continued transition from NIMH Cortex to MonkeyLogic transition:  It is essential to bridge the gap between the capabilities of new MonkeyLogic program and the capabilities of the more mature NIMH Cortex program.  Major new features are required, like support for touch screens. This requirement is the most demanding, because it requires an understanding of NIMH Cortex, its users, the internal working of MonkeyLogic, and experience with behavioral neurophysiology experimental programs, in general.  Additional steps include the implementation of a programming thread for storing hand position.     Consolidate several versions to make it easier for users to know which version to install.  Finally, the multiple versions of ML. Integrate the use of Matlab Data Acquisition Toolboxes (e.g. make Matlab fast enough to run ML) to make ML viable for the foreseeable future.  The requested will investigate a replacement from Matlab graphics.  At present Matlab graphics may prohibit presenting certain kinds of visual stimuli. The roadmap must reflect the abilities of both software packages and the needs of NIMH Cortex users as well as increase the transition to ML.  Period of Performance One year from notice of award CONTRACTING WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME) DETERMINATION The determination by the Government to award a contract without providing for full and open competition is based upon the market research conducted. Specifically, Ryklin software is the only company that may provide the requested.  Currently Ryklin is the only company that may provide mokey logic and cortex support. In order to further support the needs of NIMH it is essential that software support of both of these systems be provided by:  Ryklin Software, Inc 60 Pearl Street, 3rd Floor New York, NY 10004-2455 CLOSING STATEMENT THIS SYNOPSIS IS NOT A REQUEST FOR COMPETITIVE PROPOSALS.  However, interested parties may identify their interest and capability to respond to this notice.  Responses to this notice shall contain sufficient information to establish the interested parties’ bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.” A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government.  The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received by the closing date and time of this announcement and must reference the solicitation number.  Responses may be submitted electronically to Farrin Stanton, Contract Specialist, at Farrin.Stanton@nih.gov. US Mail and Fax responses will not be accepted.

Electrophysiology experimental mechanical rig and accessories

Department of Health and Human Services, National Institutes of Health | Published September 12, 2016  -  Deadline September 16, 2016
cpvs

INTRODUCTION This is a combined synopsis/solicitation for commercial items. This announcement constitutes the only solicitation; quotations are being requested and a written solicitation will not be issued. This acquisition is being conducted in accordance with the procedures of FAR Part 13 - Simplified Acquisition Procedures in combination with FAR 12.6 Streamlined Procedures for Evaluation and Solicitation for Commercial Items. The Solicitation Number for this acquisition is HHS-NIH-NIDA-SSSA-CSS-16-714 and the solicitation is being issued as a Request for Proposal (RFP). THIS ANNOUNCEMENT CONSTITUTES THE ONLY SOLICITATION AND A SEPARATE SOLICITATION WILL NOT BE ISSUED. SET ASIDE STATUS This is a total small business set aside.    NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE The North American Industry Classification System (NAICS) Code for this procurement is 325413          in-vitro diagnostic substance manufacturing and the Small Business Size Standard is 1250 employees. ACQUISITION AUTHORITY  This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures and FAR Part 12-Acquisition of Commercial Items, and is NOT expected to exceed the simplified acquisition threshold.  The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2005-89, dated July 15, 2016. The resultant contract will include all applicable provisions and clauses in effect through this date.  DESCRIPTION OF REQUIREMENT The National Institute of Mental Health, Laboratory for Functional Neural Circuits requires ascientifica slicescope 6000 package with accessories. ·                  Electrophysiology experimental mechanical rig and accessories ·                  SliceScope Pro 6000 with one Control Cube and one PatchPad – English w/ 1.        780nm LED System for SliceScope 2.        SliceScope filter wheel, 3 position. 3.        Polarizer, 32mm 775nm IR-DIC for BX51WIC and BX61WIF 4.        Condenser 5.7mm single position for BX/POL/DIC, stain free with NA 0.8 built in 360 degree rotatable 5.        Below Sample Prism, DIC prism for 40X water immersion objective. 6.        Above Sample Prism, high resolution DIC prism for WI-SRE-3 or WISNPXLU-2 7.        Analyzer slider for reflected light illuminator 8.        Swing Nosepiece, dual swing in/out 35 degree with DIC prism pocket, requires WI-NPA 9.        4X Objective, fluorite with working distance 17mm, numerical aperture 0.13mm 10.       40X Objective, universal working distance plan Fluorite, 3.3mm working distance, numeric aperture 0.8mm, UV to infrared. 11.       SliceScope Fluorescence Adaptor Kit 12.       Fluorescence Turret, BX light reflected illuminator for 6 fluorescence cubes. 13.      ET-GFP filter cube set, Exciter ET470/DX, Dichroic  T495LP, Emitter ET525/50m 14.      mCherry Filter cube set, exciter ET560/40X, Dichroic T585LP, Emitter ET630/75mm, peak 610 15.      Quad Wavelength LED system, 4 wavelength, power supply, microscope adaptor, pe2 collimator 16.      Imaging lens package. Lens and camera mount. 17.       Rolera Bolt Camera, 1.3 megapixel, video rate CMOS  camera, USB 2.0  12 bit noncooled, 30 frames per second. 18.      North America Multiclamp 700B 19.      DIGIDATA 1550B0 20.      pClamp 10 21.      CleanBench with ¼-20 tapped holes 22.      Full perimeter enclosure for 30” x 36” x 2” top 23.      Faraday cage 30” x 36” 24.      Set of 4 casters for 63-500 table series 25.      On track delivery for 30” x 36” table 26.      Installation and Training   ·                  Scientifica ·                  SliceScope Pro 6000 with 2X PatchStar Micromanipulators 1.        IR-DIC Components 2.        Swing NosePiece and Objectives 3.        Epifluorescence Components 4.        Imaging lens, camera mount and camera 5.        Data Acquisition 6.        Anti-vibration table 7.        Installation, training and delivery     One of the circuit mechanisms that the Laboratory for Functional Neural Circuits research focuses on concerns the role of GABAergic  interneurons in controlling the dynamics of the local network. The different types of GABAergic interneurons control information flow in cortex by targeting specific domains of excitatory pyramidal neurons, thereby controlling spatiotemporal aspects of their activity. The diversity of GABAergic INs and the microcircuits that they form, is important for understanding cortical computation. Recent advance in genetic and optical technology allows us to systematic measure and manipulate the properties of specific inhibitory neurons to address their functions. The central hypothesis of the laboratory is that, to achieve top-down modulation of sensory processing, long-range projections from higher-order cortical and neuromodulatory areas recruit specific subclasses of GABAergic INs in early sensory cortex. As a key mediator, this distinct set of GABAergic INs engage a  specific local inhibitory microcircuit thus spatiotemporally control the excitatory output. One of the laboratory’s research goals is test this hypothesis by establishing the functional connectivity of long-range inputs from cortical and neuromodulatory areas. To study the functional connectivity in the brain, our lab rely on in vitro electrophysiology system with following specifications:   1.  Installation service is required to minimize any damages caused during installation and minimizes the chance of poor equipment performance caused by mistakes in installation.   2.  Full integration of microscope objective and condenser focus, XY translation, micromanipulators, objective changing and other devices is required for simple interface display and increased productivity.   3.  Requires super-stable frame built and designed for multiple patch-clamp recording to ensure no stability issues caused by manipulation of the system. All components should be fully isolated and tested to ensure absence of electrical noise.   4.  Requires a narrow profile of a microscope frame to allow more space around the sample. This is a crucial for multiple electrode access.   5.  Both the objective focus arm and the condenser focus arm need to be motorized to adjust focus optimally on both components remotely without risking disruption of electrodes, resulting in better optical resolution and clearer images. The set-up should be convertible to in vivo recording system.   6.  Requires synchronized movement between the manipulators and the microscope stage to keep the tips of the electrodes within the field of view while the user searches for cells.   7.  Requires modular and spacious design to add large sub-stage optics for applications such as multi-photon imaging.   8.  Requires low noise during electrophysiology recordings. APPLICABLE CLAUSES AND PROVISIONS The following FAR clauses and provisions shall apply to this solicitation: 1. All Offerors MUST be actively registered in the System for Award Management (SAM) www.sam.gov. 2. The provision at FAR clause 52.212-1, Instructions to Offerors - Commercial Items (April 2014), applies to this acquisition. 3. A completed copy of the provision at FAR clause 52.212-3, Offeror Representations and Certifications - Commercial Items (March 2015), is required with any offer submitted. This requirement may be met by completion of the provision in the System for Award Management.  4. FAR clauses 52.212-4, Contract Terms and Conditions - Commercial Items (May 2015) and 52.212-5 Contract Terms and Conditions Required to Implement Statutes or Executive Orders - Commercial Items (May 2015) apply to this acquisition.  5. The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement.  In addition, the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All Offerors must have an active registration in the System for Award Management (SAM) www.sam.gov."  EVALUATION CRITERIA FAR clause 52.212-2, Evaluation - Commercial Items applies to this acquisition and the specific evaluation criteria to be included in paragraph (a) of that provision are as follows:  The Government will award a contract resulting from this solicitation on the basis of best value, technical factors and price considered. Technical factors together shall be considered more important than price. The lowest price technically acceptable proposal will be selected for award on the basis of the contractor’s ability to meet the requested items under the purpose & objectives. AWARD CRITERIA a. The acceptability of the technical portion of each contract offer will be evaluated by a technical review committee. The committee will evaluate each offer in strict conformity with the evaluation criteria of the solicitation. The committee may suggest that the Contracting Officer request clarifying information from an offeror. b. The business portion of each contract offer will be evaluated for reasonableness of the Offeror's firm to supply the services required. c. The selection for award will be based on the offer that proposes the best value to the Government. Potential for Award Without Discussions The Government reserves the right to award a contract without discussions if the Contracting Officer determines that the initial prices are fair and reasonable and that discussions are not necessary. Contracting Officer's Representative A Contracting Officer's Representative (COR) will be identified at time of award. The COR is responsible for: (1) monitoring the Contractor's technical progress, including the surveillance and assessment of performance and recommending to the Contracting Officer changes in requirements; (2) interpreting the statement of work and any other technical performance requirements; (3) performing technical evaluation as required; (4) performing technical inspections and acceptances required by this contract; and (5) assisting in the resolution of technical problems encountered during performance. The Contracting Officer is the only person with authority to act as agent of the Government under this contract. Only the Contracting Officer has authority to: (1) direct or negotiate any changes in the statement of work; (2) modify or extend the period of performance; (3) change the delivery schedule; (4) authorize reimbursement to the Contractor for any costs incurred during the performance of this contract; or (5) otherwise change any terms and conditions of this contract. The Government may unilaterally change its COTR designation. Reporting Matters Involving Fraud, Waste and Abuse Anyone who becomes aware of the existence or apparent fraud, waste and abuse in NIH funded programs is encouraged to report such matters to the HHS Inspector general's Office in writing or the Inspector general's hotline. The toll free number is 1-800-HHS- TIPS (1-800-447-8477). All telephone calls will be handled confidentially. The email address is Htips@os.dhhs.gov and the mailing address is: Office of the Inspector general Department of Health and Human Services TIPS HOTLINE PO Box 23489 Washington, DC 20026 RESPONSE FORMAT Responses to this solicitation must include clear and convincing evidence of the offeror's capability of fulfilling the requirement as it relates to the technical evaluation criteria. The offeror must submit 1) a technical response and 2) a separate price quotation. The technical response should be prepared in reference to the evaluation criteria identified in this solicitation and may be up to seven. The price quotation must include the requirements listed above as well as associated pricing.  Contractors must provide their Company Name, Dun & Bradstreet Number (DUNS), Taxpayer Identification Number (TIN), Business Size, Physical Address, and Point of Contact Information in their responses. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." NOTE Responses to this solicitation must include sufficient information to establish the interested parties' bona-fide capabilities of providing the product or service. The price quote shall include: unit price, list price, shipping and handling costs, delivery days after contract award, delivery terms, prompt payment discount terms, F.O.B. Point (Destination or Origin), product or catalog number(s); product description; and any other information or factors that may be considered in the award decision.  CLOSING STATEMENT All responses must be received by the closing date of this announcement and must reference solicitation number HHS-NIH-NIDA-SSSA-CSS-16-714. Responses shall be submitted electronically via email to Farrin Stanton , Contract Specialist, at Farrin.Stanton@nih.gov.

Dual-Channel non-invasive tissue oximeter

Department of Health and Human Services, National Institutes of Health | Published September 12, 2016  -  Deadline September 19, 2016
cpvs

Dual-Channel non-invasive tissue oximeterHHS-NIH-NIDA-SSSA-2016-PSOL-759 INTRODUCTION This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. This acquisition is being conducted in accordance with the procedures of FAR Part 13--Simplified Acquisition Procedures and FAR Part 12--Acquisition of Commercial Items. The solicitation number is HHS-NIH-NIDA-SSSA-2016-PSOL-759 and the solicitation is issued as a PRE-SOLICITATION, NOTICE OF INTENT, to award a contract on a noncompetitive basis to I.S.S. (USA) Inc, 1602 Newton Drive, Champaign, IL 61822. ACQUISITION AUTHORITY This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13--Simplified Acquisition Procedures and Subpart 6.302-1, Only one responsible source and no other supplies or services will satisfy agency requirements, and is not expected to exceed the simplified acquisition threshold. Contracts awarded using FAR Part 13--Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6--Competition Requirements. The non-competitive determination is based upon the market research conducted as prescribed in FAR Part 10--Market Research, specifically the results of market research concluded no other source of supply has the ability to provide the Dual-Channel non-invasive tissue oximeter due to the importance of consistency of the results and data, as well as the protocols and procedures that have been developed for certain particular on-going projects that this requirement would support; there are no other sources besides the proposed Contractor, who can provide the requested systems. These systems are currently in use by NINDS and to maintain consistency and continuity of science, the same exact systems must be procured as they will support the same projects. CONTRACT TYPE The Government intends to award a firm fixed price purchase order for this requirement. The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2005-89 dated August 15, 2016. NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODEThe associated NAICS code for this requirement is 334516, with a size standard 1000 Employees. BACKGROUNDThe research program of the Neuroimmunological Diseases Unit of the NINDS focuses on precision medicine care of patients with neuroimmunological diseases, especially multiple sclerosis (MS). Evidence of brain hypoxia has been seen in pathology material of some, but not all patients with MS. It is believed that brain hypoxia in MS is driven by two mechanisms: mitochondrial dysfunction and tissue hypoperfusion. However, thus far this type of subclinical brain hypoxia could not be reliably determined in living human subjects (e.g. HIF-1b, a marker used on post-mortem pathology studies is not detectable in human cerebrospinal fluid [CSF]). Neuroimmunological Diseases Unit has several ongoing clinical protocols (09-N-0197, 13-N-0088 and 09-N- 0032) where identification of patients with brain cortical microvascular tissue hypoxia is desired research/clinical goal. Using frequency-domain near-infrared spectroscopy, researchers recently confirmed reduced cortical microvascular oxygenation in MS in a blinded, case-controlled study1. Our goal is to use this technology to 1. Independently validate the observation of decreased cortical microvascular oxygenation in MS, 2. Evaluate within the context of currently ongoing open-label clinical trial of idebenone (protocol 13-N-0088), a compound which tested for its ability to enhance mitochondrial function in MS, whether idebenone enhances cortical microvascular tissue oxygenation and whether this effect correlates with the efficacy on clinical biomarkers; and finally 3. Whether subgroup of MS patients with reduced cortical microvascular tissue oxygenation differ in other aspects of disease phenotype from those patients who have brain tissue oxygenation within physiological limits. We expect that this methodology may pre-select patients who may uniquely benefit from idebenone or other tissue-oxygenation-promoting therapeutic strategies. There is currently only a single company producing frequency-domain near infrared oximeter: OxiplexTS from ISS medical. Other companies (Artinis, Vioptix, Hutchinson, Covidien) produce continuous wave near-infrared oximeters, which do not measure optical properties of the tissue in individual patients, but instead make assumptions of the optical properties of tissue based on cohort averages. Therefore, this methodology disregards individualized aspects of tissue properties and as such it introduces non-biological noise to the measurement. This technology is therefore not suitable for precision-medicine type applications. PROJECT REQUIREMENTSThe following on-going projects utilizes these systems and require the same systems to be used in order to ensure the continuity of science: Specifically the Contractor shall provide a Dual-Channel non-invasive tissue oximeter, with, but not limited to, the following specifications (see Attachment A): 0101 Dual Channel OxiplexTS 0220.2 Adult Size Lowe profile flexible sensors 0460 Auxiliary Input Interface System0461 Auxiliary Output System0722.a 2.26 GHz Portable Personal Computer Place of Performance9000 Rockville Pike10 Center DriveBethesda, MD 20892 Anticipated Period of Performance 16 weeks ARO The subject matter contractor is the only source of supply or service who can provide these systems and its associated specifications due to the importance of maintaining consistency of the results and data for the aforementioned on-going projects that already currently have in use these systems. This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. Responses to this solicitation must include sufficient information to establish the interested parties' bona-fide capabilities of providing the product or service. The price quote shall include: unit price, list price, shipping and handling costs, delivery days after contract award, delivery terms, prompt payment discount terms, F.O.B. Point (Destination or Origin), product or catalog number(s); product description; and any other information or factors that may be considered in the award decision. Such factors may include: past performance; special features required for effective program performance; trade-in considerations; probable life of the item selected as compared with that of a comparable item; warranty considerations; maintenance availability; and environmental and energy efficiency considerations. The following FAR provisions shall apply to this solicitation: 52.212-1, Instructions to Offerors--Commercial Items, 52.212-2, Evaluation--Commercial Items. Evaluation factors that will be used to evaluate the offer most advantageous to the Government, price and other factors considered, include ability to meet the technical requirements stated in this pre-solicitation and on basis of best value to the government. Offerors must include a completed copy of the provision at 52.212-3, Offeror Representations and Certifications Commercial Items, with their offer. The Clause at 52.212-4, Contract Terms and Conditions Commercial Items, applies to this acquisition and the Clause at 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders Commercial Items applies to this acquisition. The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement. In addition the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All Offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency. All responses must be received by September 19, 2016 at 12:00 pm, Eastern Standard Time (EST) and must reference solicitation number HHS-NIH-NIDA-SSSA-PSOL-2016-759. Responses may be submitted electronically to amcgee@mail.nih.gov and to NIDASSSAPurchaseRequ@mail.nih.gov or by U.S. mail to the National Institute of Drug Abuse (NIDA), Station Support / Simplified Acquisition Branch (SS/SA), 31 Center Drive, Building 31, Room 1B59, Bethesda, Maryland 20892-2080, Attention: Andrea McGee. Fax responses will be accepted at (301) 480-1358. For information regarding this solicitation, contact Andrea McGee by email at amcgee@mail.nih.gov or by phone at (301) 480-2449.